EDGAR Online, Inc. (EDGR) Files Investor Presentation in Connection with November 18, 2010 Meeting of Stockholders

David L. Price, Chief Financial Officer, EDGAR Online, Inc., +1-212-457-8200, dprice@edgar-online.com

LSI Industries Inc. (LYTS) Reports Operating Results for the First Quarter Ended September 30, 2010

CINCINNATI, Oct. 21, 2010 (GLOBE NEWSWIRE) — LSI Industries Inc. (Nasdaq:LYTS) today:

• reported first quarter net sales of $79,851,000, an increase of 18% as compared to the same period of the prior fiscal year;
• reported first quarter net income of $4,268,000 or $0.18 per share, as compared to net income of $1,637,000 or $0.07 per share for the same period of the prior fiscal year; and
• declared a regular quarterly cash dividend of $0.05 per share payable November 9, 2010 to shareholders of record November 2, 2010.

First Quarter Fiscal 2011 Results

Net sales in the first quarter of fiscal 2011 were $79,851,000, an increase of 18.0% over last year’s first quarter net sales of $67,676,000. Lighting Segment net sales increased 19.8% to $47,475,000 (sales to national accounts and niche markets increased 31.2% and sales to the Commercial / Industrial lighting market increased 10.4%), Graphics Segment net sales increased 18.1% to $26,087,000, Electronic Components Segment net sales increased 41.0% to $4,564,000 and net sales of the All Other Category decreased 36.1% to $1,725,000. The fiscal 2011 first quarter net income of $4,268,000 or $0.18 per share, compares to a fiscal 2010 first quarter net income of $1,637,000, or $0.07 per share. First quarter fiscal 2010 results included pre-tax expenses of acquisition deal costs of $513,000 and an acquisition-related fair value inventory adjustment of $526,000 related to purchase accounting requirements of LSI ADL Technology’s finished goods and work-in-process inventory. Earnings per share represents diluted earnings per share.

Reportable Business Segments

The Company made two changes to its reportable business segments in fiscal 2011. The Technology Segment was reclassified into the All Other Category because there were no quantitative measures or qualitative factors that required the operating results of LSI Saco Technology to be reported as a separate business segment. The Company also reclassified its Corporate Administration expense out of the All Other Category and into a separate line item in the business segment disclosures. These changes were made for all reported periods in the financial information presented, and they had no impact on the Company’s consolidated results.

Company Comments

Robert J. Ready, President and Chief Executive Officer, commented, “In LSI Industries’ year-end press release and letter to shareholders in the Annual Report for fiscal 2010, I reported to you in some detail on the various actions taken in connection with our theme of ‘preparation and change.’ I also remarked that our overall strategic growth vision had not wavered as LSI continues its commitment to developing new product technologies for its markets while maintaining and growing its world class lighting and graphics capabilities. I stated ‘The potential of LSI Industries resides in how we think about our long-term growth strategies while we employ short-term oriented tactics and actions to cut costs, improve efficiencies, and remain financially sound.’ Finally, I commented that LSI was well positioned to capitalize on an improving economy and the markets served.

“I am pleased to report that we are now beginning to reap the benefits of our ‘preparation and change’ work as evidenced by the operating results achieved for the fiscal 2011 first quarter ended September 30, 2010. On an increase in net sales of 18%, net income increased 88% over the same period of the prior year (after disregarding acquisition related costs incurred in the first quarter of fiscal 2010). While we are proud of the increase in sales, we also believe these operating results demonstrate that LSI is being operated on a very efficient basis and will enjoy favorable operating leverage to its earnings as net sales increase.

“Looking forward we are optimistic about our continued growth in solid-state LED lighting. Our recently introduced Crossover® Generation 3 product line has been very well received and is a market leader resulting in increasing unit sales and a broader customer base. Lighting solutions geared to energy reduction are popular in all markets and we have a number of new products that will be released during the second quarter of this fiscal year that will continue to fuel the growth of our advanced fluorescent and solid-state LED products. LSI continues to lead the way in advanced energy-efficient lighting and graphics products. We believe we also made very good progress in the establishment of a distribution channel to the European and Middle East markets for our solid-state LED lighting products and have obtained nearly all required European product certifications. This is expected to lead to sales growth in new markets for LSI in the near future.

“In summary, we are off to a strong start in fiscal 2011. LSI is well positioned to capitalize on sales opportunities in our niche and general markets with advanced lighting and graphics products and services. I look forward to keeping you posted on our progress and important developments as the fiscal year unfolds. As a reminder, LSI will be holding its Annual Shareholder Meeting on November 18, 2010. We cordially invite shareholders to attend.”

Balance Sheet

The balance sheet at September 30, 2010 included current assets of $102.2 million, current liabilities of $24.8 million and working capital of $77.4 million. The current ratio was 4.12 to 1. The Company has shareholders’ equity of $147.6 million, $1.1 million of long-term debt, and has borrowing capacity on its commercial bank facilities as of September 30, 2010 of $35 million. With continued strong cash flow, a sound and conservatively capitalized balance sheet, and $35 million in credit facilities, LSI Industries believes its financial condition is sound and capable of supporting the Company’s planned growth, including acquisitions.

Cash Dividend Actions

The Board of Directors declared a regular quarterly cash dividend of $0.05 per share payable November 9, 2010 to shareholders of record as of November 2, 2010. The indicated annual cash dividend rate for fiscal 2011 is $0.20 per share. LSI Industries has paid regular cash dividends since 1989. The declaration and amount of any cash and stock dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments and opportunities, including acquisitions.

Non-GAAP Financial Measures

This press release includes adjustments to the GAAP net income for the three month period ended September 30, 2009. Adjusted net income and earnings per share, which excludes the impact of the LSI ADL Technology acquisition deal costs and acquisition-related fair value inventory adjustment is a non-GAAP financial measure. We believe that it is useful as a supplemental measure in assessing the operating performance of our business. This measure is used by our management, including our chief operating decision maker, to evaluate business results. We exclude these non-recurring items because they are not representative of the ongoing results of operations of our business. Below is a reconciliation of this non-GAAP measure to net income for the period indicated, excluding the acquisition related costs.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This document contains certain forward-looking statements that are subject to numerous assumptions, risks or uncertainties. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Forward-looking statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “expects,” “intends,” “believes,” “seeks,” “may,” “will,” “should” or the negative versions of those words and similar expressions, and by the context in which they are used. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Actual results could differ materially from those contained in or implied by such forward-looking statements as a result of a variety of risks and uncertainties over which the Company may have no control. These risks and uncertainties include, but are not limited to, the impact of competitive products and services, product demand and market acceptance risks, potential costs associated with litigation and regulatory compliance, reliance on key customers, financial difficulties experienced by customers, the cyclical and seasonal nature of our business, the adequacy of reserves and allowances for doubtful accounts, fluctuations in operating results or costs whether as a result of uncertainties inherent in tax and accounting matters or otherwise, unexpected difficulties in integrating acquired businesses, the ability to retain key employees of acquired businesses, unfavorable economic and market conditions, and the results of asset impairment assessments. You are cautioned to not place undue reliance on these forward-looking statements. In addition to the factors described in this paragraph, the risk factors identified in our Form 10-K and other filings the Company may make with the SEC constitute risks and uncertainties that may affect the financial performance of the Company and are incorporated herein by reference. The Company does not undertake and hereby disclaims any duty to update any forward-looking statements to reflect subsequent events or circumstances.

About the Company

LSI Industries Inc. is an Image Solutions company, dedicated to advancing solid-state LED technology in lighting and graphics applications. We combine integrated technology, design, and manufacturing to supply high quality, environmentally friendly lighting fixtures and graphics elements for commercial, retail and specialty niche market applications. LSI is a U.S. manufacturer with marketing / sales efforts throughout the world with concentration currently on North American, Latin American, Australian, New Zealand, Asian, European and Middle Eastern markets.

Building upon its success with its Crossover^® LED lighting fixtures and SmartVision^® solid-state LED video boards, LSI is committed to producing affordable, high performance, energy efficient lighting and graphic products for indoor and outdoor use. We have a vast offering of innovative solutions for virtually any lighting or graphics application. Further, we can provide design support, engineering, installation and project management for custom graphics rollout programs for today’s retail environment.

LSI’s major markets are the commercial / industrial lighting, petroleum / convenience store, multi-site retail (including automobile dealerships, restaurants and national retail accounts), sports and entertainment markets. LSI employs approximately 1,500 people in facilities located in Ohio, New York, North Carolina, Kansas, Kentucky, Rhode Island, Texas and Montreal, Canada. The Company’s common shares are traded on the NASDAQ Global Select Market under the symbol LYTS.

The LSI Industries Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3646

For further information, contact either Bob Ready, Chief Executive Officer and President, or Ron Stowell, Vice President, Chief Financial Officer, and Treasurer at (513) 793-3200.

Additional note: Today’s news release, along with past releases from LSI Industries, is available on the Company’s internet site at www.lsi-industries.com or by email or fax, by calling the Investor Relations Department at (513) 793-3200. More information on LSI’s quarterly earnings, including additional financial analysis and an earnings overview presentation, will also be available at this site after the Investor Call to be held at 3:00 p.m. Eastern Time today.

CONTACT:  LSI Industries Inc.
          Bob Ready
          Ron Stowell
          (513) 793-3200

Vera Bradley (VRA) Announces Pricing of Its Initial Public Offering

FORT WAYNE, Ind., Oct. 21, 2010 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq:VRA) announced today that it has priced its initial public offering of 11,000,000 shares of its common stock at $16.00 per share. Vera Bradley has agreed to sell 4,000,000 shares and selling shareholders have agreed to sell 7,000,000 shares. The shares will be listed on the Nasdaq Global Select Market under the symbol “VRA” and will begin trading today. In addition, the underwriters have a 30-day option to purchase up to 1,650,000 additional shares from the selling shareholders at the initial public offering price to cover over-allotments, if any. Vera Bradley, Inc. will not receive any proceeds from the sale of shares by the selling shareholders.

Robert W. Baird & Co. Incorporated and Piper Jaffray & Co. acted as joint book-running managers for the offering. Wells Fargo Securities, LLC, KeyBanc Capital Markets Inc. and Lazard Capital Markets acted as co-managers of the offering.

The offering of these securities will be made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained by contacting: Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI  53202, telephone: 800-792-2413 or email syndicate@rwbaird.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, telephone: 800-747-3924 or email: prospectus@pjc.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 20, 2010. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vera Bradley

Friends Barbara Bradley Baekgaard and Patricia R. Miller founded Vera Bradley in 1982. Today, Vera Bradley is sold through 3,300 specialty stores as well as 35Vera Bradley stores nationwide. Vera Bradley accessories, handbags, travel and paper & gift items have recently been spotted on: Desperate Housewives, Brothers and Sisters, Entourage, Modern Family and in over 20 feature-length films. Visit www.verabradley.com for a store near you or to learn more.

CONTACT:  Vera Bradley
          Public Relations:
          877-708 VERA (8372)
          Mediacontact@verabradley.com

          ICR, Inc.
          Investor Relations:
          Joseph Teklits
          Jean Fontana
            Jean.fontana@icrinc.com
          203-682-8200

Rexahn Pharmaceuticals (RNN) Publishes New Data on Anti-Cancer Isoquinolinamine Derivatives

ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry [45:5493-5497, 2010].

In the study, various substituted 3-aryl-1-isoquinolinamine derivatives were shown to have excellent cytotoxicity against eight different human cancer cells (breast, prostate, colon, ovary, kidney, pancreas, glioblastoma, melanoma). These derivatives were synthesized and evaluated through the constructed QSAR (quantitative structure-activity relationship) model and in vitro cell studies. QSAR technique is used in drug design and virtual screening to find lead compounds. The cytotoxic activities of new designed compounds are calculated using the constructed QSAR model and compared with actual cytotoxic data using the synthesized compounds.

“In this second published study, we further establish that isoquinolinamine derivatives, such as our anti-cancer compound RX-8243 – a new chemical entity – are potent anti-cancer compounds that have the potential to be developed into chemotherapeutic agents,” said Rick Soni, President of Rexahn.

Last month Rexahn announced the publication of new preclinical data in Bioorganic & Medicinal Chemistry Letters demonstrating that RX-8243, an isoquinolinamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol^®) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing best in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ – all potential best in class therapeutics – and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn’s licensees or sublicensees; the success of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Opto Circuits to Acquire Cardiac Science (CSCX)

BOTHELL, Wash. and BANGALORE, KARNATAKA, India — Cardiac Science Corporation (Nasdaq: CSCX) and Opto Circuits (India) Limited [BSE Code: 532391; NSE: OPTOCIRCUI] today announced they have entered into a definitive merger agreement under which Opto Circuits has agreed to acquire all of the outstanding shares of Cardiac Science common stock for $2.30 USD per share.  The $2.30 price represents a 10% premium to the closing price of Cardiac Science common stock of $2.10 on October 18, 2010, a 28% premium to the average closing price for the 30 day period ended October 18, 2010 and a 30% premium to the average closing price for the 100 day period ended October 18, 2010.

“We believe this transaction provides excellent value to our shareholders and expanded opportunity for our customers, employees, and partners,” said Dave Marver, Cardiac Science president and chief executive officer. “Our business will benefit greatly from Opto Circuits’ financial resources, operational capabilities, and global scale.”

“We are delighted to expand our presence in noninvasive diagnostic monitoring through this acquisition and are excited to enter the high-growth automated external defibrillation market,” said Vinod Ramnani, Opto Circuits chairman and managing director. “Cardiac Science has a strong reputation for innovative, high-quality products and services. This transaction is expected to open many new global markets for Cardiac Science’s products and will greatly enhance Opto Circuits’ product offering and presence in the United States.”

Piper Jaffray acted as financial advisor to Cardiac Science and delivered a fairness opinion to Cardiac Science’s board of directors. Perkins Coie LLP served as outside legal counsel to Cardiac Science, while Quarles & Brady LLP served as outside legal counsel to Opto Circuits.

About the Transaction

The boards of directors of both companies have unanimously approved the transaction, which will take the form of an all-cash tender offer by a wholly-owned subsidiary of Opto Circuits, followed by a second-step merger.  The closing of the tender offer by Opto Circuits, which is expected to be commenced within 10 business days, is subject to customary conditions, including that shares representing at least sixty percent (60%) of Cardiac Science’s outstanding shares of common stock are validly tendered into the offer. As a result of the second-step merger, any shares that have not been validly tendered into the offer will be converted into the right to receive cash equal to the offer price of $2.30 per share.  The subsequent closing of the merger may be subject to obtaining stockholder approval of the merger agreement if Opto Circuits does not acquire a sufficient number of shares to effect a short-form merger. If such approval is needed, Cardiac Science will call a special meeting of its stockholders. If a stockholder meeting is required to approve the merger, Opto Circuits has agreed to vote (or cause its acquisition subsidiary to vote) all shares of Cardiac Science it owns in favor of the merger.  The companies are targeting a late fourth quarter 2010 closing, assuming satisfaction of closing conditions and successful execution of the tender offer process.

Upon completion of the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits.  Opto Circuits will fund the purchase with its cash and credit lines.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmills and systems, diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

About Opto Circuits

Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is an Indian MNC in the business of design, development, manufacture and marketing of healthcare equipment and interventional products. The product profile includes pulse oximeters, patient monitoring systems, sensors, digital thermometers, anesthesia and respiratory care equipment, stents, catheters and other innovative products. Some of the well-known brands marketed by Opto Circuits are Criticare, Mediaid, Unetixs and Eurocor. It is presently a Group of 14 companies with a consolidated total sales of USD $243 million/Rs.1077 crores (FY10) and it is headquartered in Bengaluru, Karnataka, India. Its key markets are the US, Europe and South East Asia. It was ranked as one amongst 200 Best Under a Billion companies in AsiaPac by Forbes Asia in 2009, 2008.  Visit us at www.optoindia.com

Important Additional Information

The tender offer for the outstanding common stock of Cardiac Science referred to in this press release has not yet commenced. This press release is neither an offer to purchase nor a solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of Cardiac Science’s common stock will be made pursuant to an offer to purchase and related materials that Opto Circuits and a wholly-owned subsidiary of Opto Circuits intend to file with the Securities and Exchange Commission. At the time the offer is commenced Opto Circuits and its wholly-owned subsidiary will file a tender offer statement on Schedule TO with the Securities and Exchange Commission, and thereafter the Company will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. The tender offer statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement will contain important information that should be read carefully and considered before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of the Company when available. In addition, all of these materials (and all other materials filed by the Company with the Securities and Exchange Commission) will be available at no charge from the Securities and Exchange Commission through its website at www.sec.gov. Investors and security holders may also obtain free copies of the tender offer documents, once available, from the information agent for the tender offer or by mailing a request to Cardiac Science Corporation, Attention: Investor Relations, 3303 Monte Villa Parkway, Bothell, Washington 98021.

Forward-Looking Statements

This release contains forward-looking statements regarding the proposed acquisition of Cardiac Science, the expected timetable for completing the transaction, future business prospects and market conditions and benefits and synergies of the transaction. Such statements are based on the current assumptions and expectations of Cardiac Science’ and Opto Circuits’ management and are neither promises nor guarantees. The words “believe,” “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. There can be no assurance that management’s estimates of future results will be achieved. Actual results and performance may vary significantly from those expressed or implied in such statements. The actual results of the acquisition could vary materially as a result of a number of factors, including: uncertainties as to how many of Cardiac Science Corporation’s stockholders will tender their stock in the tender offer; the possibility that competing offers will be made; and the possibility that various closing conditions for the transaction may not be satisfied or waived. Other factors that may cause actual results to differ materially include those set forth in the reports that Cardiac Science files from time to time with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2009 and quarterly and current reports on Form 10-Q and 8-K. These forward-looking statements reflect Cardiac Science Corporation’s expectations as of the date of this document. Cardiac Science Corporation undertakes no obligation to update the information provided herein.

NuPathe (PATH) Announces Positive Top-Line Results From 12 Month Safety Trial for Zelrix(TM)

CONSHOHOCKEN, PA — (Marketwire) — 10/19/10 — NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announces positive top-line results from a 12 month open-label, safety trial for Zelrix. The company also announces the development of an in vitro analytical testing method for Zelrix, as requested by the U.S. Food and Drug Administration (FDA), to confirm the amount of sumatriptan delivered. Zelrix is a single-use, transdermal sumatriptan patch in development for the treatment of migraine.

“With strong results from this long term, open-label safety trial and the development of an in vitro analytical method for Zelrix, we continue to make steady progress toward the submission of a New Drug Application (NDA) prior to year end,” said Jane Hollingsworth, chief executive officer of NuPathe. “Based upon the growing body of clinical evidence, we believe Zelrix, if approved, should provide an efficacious and well-tolerated treatment option for many of the millions of underserved migraine patients in the U.S. in a novel transdermal formulation.”

The 12 month study (NP101-008) was an open-label trial designed to assess the long term safety of Zelrix. A total of 183 patients were enrolled and applied at least one Zelrix patch. Importantly, and consistent with findings from the Zelrix Phase III pivotal trial, Zelrix was well tolerated and the incidence of triptan-related adverse events was very low, with only three patients (1.6 percent) reporting a triptan adverse event with any Zelrix treatment over the course of the 12 month trial.

The most common adverse events were related to the patch application site and included application site itching (21.9 percent of patients), application site pain (21.3 percent) and application site hypersensitivity (6.0 percent). During the 12 month trial, 25 patients (13.7 percent) discontinued participation due to adverse events, which were primarily due to application site reactions. There was no observed increase in skin irritation with successive or cumulative patch usage.

In addition to assessing safety, this trial evaluated patients’ efficacy responses two hours after application of Zelrix when treating a migraine with headache pain rated moderate to severe. Efficacy highlights include:

• Achievement of headache pain relief within two hours for 58 percent of migraines treated
• Achievement of headache pain freedom within two hours for 24 percent of migraines treated
• Achievement of freedom from nausea within two hours for 79 percent of migraines treated
• Rescue medication used in only 19 percent of migraines treated

“The safety and tolerability of Zelrix in this 12 month trial was consistent with the profile observed in the pivotal Phase III trial for Zelrix in which only a single migraine was treated,” commented Mark Pierce, MD, PhD, chief scientific officer of NuPathe. “Additionally, the results demonstrate strong and consistent efficacy throughout the duration of the trial.” NuPathe plans to present detailed results from the trial at a scientific meeting in 2011.

About Zelrix
Zelrix is an active, single-use, transdermal sumatriptan patch in development for the treatment of migraine. Zelrix is designed to provide migraine patients fast onset and sustained relief through a tolerable, non-oral route of administration. We believe Zelrix may provide a better alternative for many migraine patients by circumventing treatment-altering nausea and vomiting, by increasing consistency of response, and by minimizing the incidence of triptan adverse events. Zelrix is powered by SmartRelief™, our proprietary transdermal delivery technology. SmartRelief consists of a controlled delivery technology that uses a mild electrical current to actively transport medication through the skin using a process called iontophoresis.

About Migraine
Migraine is a debilitating neurological disease that affects approximately 28 million people in the U.S. Symptoms of migraine include moderate to severe headache pain, nausea and vomiting, photophobia, and phonophobia. Most migraines last between four and 24 hours, but some last as long as three days. According to published research, 63 percent of migraine sufferers experience between one and four migraines per month.

In a majority of their migraines, most patients suffer from one or more significant gastrointestinal problems, which include nausea, vomiting and a compromised ability to digest, known as decreased gastric motility. Nausea and vomiting often impede the use of oral medications, while reduced gastric motility can result in inconsistent efficacy. According to a survey with over 500 respondents conducted by the National Headache Foundation in 2008, 90% of migraine patients have experienced nausea with a migraine and 59% of migraine patients have experienced vomiting with a migraine. In this survey, 48% of respondents who ever experienced nausea or vomiting with a migraine reported that the nausea or vomiting had a moderate to major impact on when or how they take migraine medications.

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s most advanced product candidate, Zelrix, is a single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.

Forward-Looking Statements

All statements contained in this press release that are not statements of historical facts are hereby identified as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, (i) our interpretation of clinical data from the referenced trials and our plan to present such data at a scientific meeting in the future, (ii) the timing of the submission of our NDA for Zelrix, and (iii) the potential benefits of, and market for, Zelrix and our other product candidates. The words “may,” “will,” “intend,” “plan,” “anticipate,” “believe,” “potential,” “continue,” “should,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties relating to: (i) our ability to timely complete clinical and preclinical trials, (ii) varying interpretation of clinical data from the referenced trials, (iii) FDA acceptance of the in vitro analytical testing method we developed for Zelrix, and (iv) serious adverse events or other safety risks that could require us to abandon or delay development, and preclude or limit approval of, Zelrix. For further information with respect to these and other factors that could cause actual results to differ materially from those indicated in this press release, reference is made to the “Risk Factors” section of our From 10-Q for the quarter ended June 30, 2010, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements contained in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

MEDIA CONTACTS
Ron Schmid
NuPathe Inc.
(610) 659-3985

INVESTOR CONTACTS
John Woolford
(443) 213-0506
Email Contact

Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130

Atlantic Coast Federal Corporation (ACFC) Reports Third Quarter 2010 Results

Oct. 19, 2010 (Business Wire) — Atlantic Coast Federal Corporation (NASDAQ:ACFC), the holding company for Atlantic Coast Bank, today reported financial results for the three and nine months ended September 30, 2010. Highlights of the Company’s third quarter report included:

• A 72% decline in a loss before income taxes to $2.2 million for the third quarter of 2010 from $7.7 million in the year-earlier quarter, continuing an improving trend seen over the past year;
• A 56% decline in a loss before income taxes, excluding a goodwill impairment charge of $2.8 million in the third quarter of 2009;
• An ongoing year-over-year improvement in net interest margin, contributing to a 5% increase in net interest income for the third quarter of 2010 compared with the same quarter last year;
• Relative stability in non-performing loans and assets, which peaked in mid-2009; and
• Lower levels of net charge-offs, which contributed to a 54% decrease in the Company’s provision for loan losses for the third quarter of 2010 compared with the year-earlier quarter and a decrease of 59% versus the provision for the second quarter of 2010.

On an after-tax basis, the Company recorded a net loss of $2.2 million or $0.16 per diluted share for the third quarter of 2010 compared with a net loss of $12.2 million or $0.93 per diluted share for the year-earlier quarter. For the first nine months of 2010, the net loss totaled $9.0 million or $0.68 per diluted share compared with a net loss of $19.9 million or $1.52 per diluted share for the first nine months of 2009. The Company no longer records the income tax benefit of its net losses following the establishment of a deferred tax asset valuation allowance during 2009. The inability to recognize an income tax benefit increased the net loss in the third quarter of 2009 by $4.5 million or $0.34 per diluted share.

“While we continue to deal with a slow economic recovery, especially in north Florida where the real estate market remains weak, we are encouraged to see that our problem assets have leveled off despite these conditions,” said Robert J. Larison, Jr., President and Chief Executive Officer. “Together with a declining level of net charge-offs for the quarter, the stability of our non-performing loans positioned us to reduce our provision for loan losses, leading to lower overall credit costs for the quarter versus both the year-earlier period and the linked quarter. Strategically, we also are pleased with the emerging growth in profits from our warehouse loan program and the expansion of our mortgage lending business in the third quarter of 2010. We believe both of these lending activities, along with planned expansion of small business lending, provide us with a solid response to a low-rate environment by enabling us to capture both incremental spread and fees on very short-term lending.”

Jay S. Sidhu, Executive Chairman of the Board, added, “Stabilizing the level of our non-performing assets is an important step for Atlantic Coast Bank. It allows us to begin to focus on developing other aspects of the bank, such as the expansion of mortgage banking and small business lending, both of which we expect to gain momentum over the next several quarters. These expanded business lines will re-characterize our balance sheet over time, positioning the Bank for future revenue growth that will complement net interest income. Strengthening our capital levels also remains the primary objective of our Board, and so we remain committed to completing our second-step conversion in 2010. This will allow Atlantic Coast Bank to grow in support of the communities we serve and put us in a position to execute on our longer-term strategies.”

Capital Position

The Bank’s Tier 1 leverage ratio, Tier 1 risk-based capital ratio and Total risk-based capital ratio were 5.6%, 9.4%, and 10.7% respectively, at September 30, 2010, and continued to exceed the required minimums of 5%, 6%, and 10%, respectively, necessary to be deemed a well-capitalized institution. In addition, stockholders’ equity represented 5.76% of total assets at that date.

The following tabular presentations highlight other key aspects of the Company’s performance:

• The higher amount of net charge-offs in the second quarter of 2010 reflected losses of $ 2.8 million on the sale of two pools of non-performing loans along with losses of $3.3 million on a commercial multi-family development and $1.0 million on a commercial real estate property.

• The higher provisions for loan losses in the second quarter of 2010 and the year-earlier quarter reflected increased net charge-offs in those periods.
• The Company remains conservative in its methodology for identifying problem loans early in the cycle and aggressive in charging down residential and home equity loans on the date such loans become non-performing.

• The year-over-year increase in net interest margin primarily reflects a reduction in the Company’s funding costs due to a run-off of higher-rate certificates of deposit, as well as the positive impact of the Company’s expanded loan warehouse program.
• The decline in net interest margin from the second quarter of 2010 was due primarily to decreases in yields earned on investment securities. Generally, interest rates on securities purchased to replace securities that have matured or been sold are at much lower interest rates.

• In the third quarter of 2010 the Company recorded a $1.2 million loss on the sale of private-label collateralized mortgage obligations, which was partially offset by a $0.8 million gain on the sale of available-for-sale securities; the period also included $0.4 million of gains on the sales of portfolio loans and loans held for sale.
• In the second quarter of 2010 gains on sales of portfolio loans, loans held for sale, and available-for-sale securities, net of other-than-temporary impairment losses, totaled $1.4 million; in the third quarter of the prior year, this amount was $0.7 million.
• The increase in non-interest expense in the third quarter of 2010 reflected primarily additional write-downs on foreclosed assets, offsetting the positive impact of lower compensation and benefits expense year-over-year due to expense reduction initiatives implemented during 2009, and lower occupancy costs related to the relocation of the Florida corporate headquarters as well as the sale of a branch office in 2009.
• Non-interest expense in the year-earlier quarter also included a $2.8 million goodwill impairment charge.
• The combination of improved net interest income, higher non-interest income and lower non-interest expense for the year-to-date period in 2010 has resulted in an improved efficiency ratio.

• The Company established a valuation reserve for the full amount of its deferred tax asset during 2009. Accordingly, the Company no longer records the income tax benefit of net losses until such time it determines that realization of the deferred tax asset is more likely than not.

About the Company

Atlantic Coast Federal Corporation is the holding company for Atlantic Coast Bank, a federally chartered and insured stock savings association organized in 1939 as a credit union to serve the employees of the Atlantic Coast Line Railroad. Today, Atlantic Coast Bank is a community-oriented financial institution serving southeastern Georgia and northeastern Florida through 12 locations, including a focus on the Jacksonville metropolitan area. Investors may obtain additional information about Atlantic Coast Federal Corporation on the Internet at www.AtlanticCoastBank.net, under Investor Information.

Forward-looking Statements

This news release contains forward-looking statements within the meaning of the federal securities laws. Statements in this release that are not strictly historical are forward-looking and are based upon current expectations that may differ materially from actual results. These forward-looking statements, identified by words such as “will,” “expected,” “believe,” and “prospects,” involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. These risks and uncertainties involve general economic trends and changes in interest rates, increased competition, changes in consumer demand for financial services, the possibility of unforeseen events affecting the industry generally, the uncertainties associated with newly developed or acquired operations, and market disruptions and other effects of terrorist activities. The Company undertakes no obligation to release revisions to these forward-looking statements publicly to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events, except as required to be reported under the rules and regulations of the Securities and Exchange Commission.

A registration statement relating to the securities to be offered in the second step offering has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy shares of common stock nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities are not savings accounts or savings deposits, may lose value and are not insured by the Federal Deposit Insurance Corporation or any government agency.

Atlantic Coast Federal Corporation has filed a proxy statement/prospectus concerning the conversion with the Securities and Exchange Commission. Stockholders of Atlantic Coast Federal Corporation are urged to read the proxy statement/prospectus because it contains important information. Investors are able to obtain all documents filed with the Securities and Exchange Commission by Atlantic Coast Federal Corporation and Atlantic Coast Financial Corporation free of charge at the Securities and Exchange Commission’s website, www.sec.gov. In addition, documents filed with the Securities and Exchange Commission by Atlantic Coast Federal Corporation and Atlantic Coast Financial Corporation are available free of charge from the Corporate Secretary of Atlantic Coast Federal Corporation at 505 Haines Avenue, Waycross, Georgia 31501, Attention: Corporate Secretary.

The directors, executive officers, and certain other members of management and employees of Atlantic Coast Federal Corporation are participants in the solicitation of proxies in favor of the conversion from the stockholders of Atlantic Coast Federal Corporation. Information about the directors and executive officers of Atlantic Coast Federal Corporation is included in the proxy statement/prospectus filed with the Securities and Exchange Commission.

Selected Consolidated Financial Ratios and Other Data (unaudited) for the third quarter and nine months ended September 30, 2010 and 2009, may be found at the following link: http://www.irinfo.com/acfc/ACFC3Q10ejc.pdf. Investors should refer to the Company’s Form 10-Q for the quarter ended September 30, 2010, for additional information and disclosures; the Form 10-Q will be available at the Investor Information section of the Company’s website immediately upon filing with the Securities and Exchange Commission.

Jacada (JCDA) Signs Agreement with Blue Cross Blue Shield of Massachusetts

Oct. 19, 2010 (Business Wire) — Jacada Ltd. (NASDAQ: JCDA), a leading provider of customer experience management and process optimization solutions for customer service operations, signs agreement with Blue Cross Blue Shield of Massachusetts (BCBSMA) to provide Jacada Fusion Integration Technologies in support of streamlining their technology services and accelerating their move to Service Oriented Architecture (SOA). This solution will allow BCBSMA to easily integrate and exchange data for critical host-based, web-based and Windows applications.

“We are thrilled to have the opportunity to work with Blue Cross Blue Shield of Massachusetts and to provide them with the critical integration technology necessary to support their Healthcare Services initiative,” said Tom Clear, chief executive officer for Jacada. “Providing superior customer service is paramount to healthcare organizations in today’s world and I look forward to working with BCBSMA in support of this goal.”

Jacada Fusion® is a non-invasive platform designed to increase agent productivity and improve the customer experience – without requiring any modifications to existing business applications. Jacada Fusion leverages the current IT environment and in-place assets.

“Using Jacada Integration Technologies will allow BCBSMA to service enable a number of our legacy systems while we invest in reengineering and replacing applications,” said Ted Marsh, Chief Technology Officer at BCBSMA. “This technology will help us integrate our legacy assets into a comprehensive SOA platform, enabling us to become more agile and responsive to changing business needs given the dynamic healthcare environment. Jacada is a proven leader in this area and we are pleased to be working with a dedicated team of professionals.”

About Blue Cross Blue Cross Blue Shield of Massachusetts

Blue Cross Blue Shield of Massachusetts (www.bluecrossma.com) was founded 73 years ago by a group of community-minded business leaders. Today, headquartered in Boston, BCBSMA provides coverage to nearly 3 million members. BCBSMA believes in rewarding doctors and hospitals for delivering safe and effective care, and in empowering patients to take more responsibility, become educated health care consumers, and become stronger partners with their doctors. Blue Cross Blue Shield of Massachusetts is an independent licensee of the Blue Cross Blue Shield Association.

About Jacada

Jacada is a leading global provider of customer experience management and interaction optimization solutions. By bridging disconnected systems and processes, Jacada solutions create greater operational efficiency and increase agent and customer satisfaction. Founded in 1990, Jacada operates globally with offices in London; Munich; Stockholm; Atlanta, Georgia; and Herzliya, Israel. Jacada can be reached at www.jacada.com.

This news release may contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. The words “may,” “could,” “would,” “will,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of the future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the performance and continued acceptance of our products, general economic conditions and other Risk Factors specifically identified in our reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made. Jacada is a trademark of Jacada Inc. All other brands or product names are trademarks of their respective owners.

Jacada Media:

Jennifer Childress, 770-776-2239

jchildress@jacada.com

Peregrine (PPHM) Reports Promising Interim Survival Data From Phase II Cotara(R) Brain Cancer Study

TUSTIN, CA and SAN FRANCISCO, CA — (Marketwire) — 10/18/10 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today reported interim data from an ongoing Phase II clinical trial of its novel brain cancer therapy Cotara®. Interim median overall survival was 86 weeks for a cohort of 14 patients with glioblastoma multiforme (GBM) treated at first relapse with a single infusion of Cotara. Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered directly into the tumor, destroying the tumor from the inside out, with minimal exposure to healthy tissue.

“Interim survival data from patients treated with Cotara have been encouraging, previously ranging from 38 to 41 weeks, when expected survival for these patients is typically 24 weeks from time of disease recurrence,” said Joseph S. Shan, M.P.H., vice president, clinical and regulatory affairs of Peregrine Pharmaceuticals. “We look forward to completing enrollment of the few remaining patients in this Phase II trial before the end of this year and reporting data by mid-year next year. Once this trial is completed and we have analyzed the data, we plan to meet with the FDA to determine the optimal registration pathway for Cotara.”

As part of an ongoing Phase II clinical trial of 40 patients with GBM at first relapse, 15 GBM patients (mean age 48.5 years) were enrolled at the All India Institute of Medical Sciences (AIIMS) in New Delhi, India, the lead clinical site. Interim data available for 14 of these patients showed median overall survival of 86 weeks and follow-up duration ranges from between four and 107 weeks. Cotara has been granted orphan drug status and Fast Track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration (FDA).

“Overall median survival of 86 weeks far exceeded our expectations in this very difficult to treat patient population where treatment options are few and rarely extend median survival beyond six months,” said Deepak Gupta, M.D., assistant professor of neurosurgery at AIIMS. “Interim data indicate that Cotara appears well-tolerated and active in GBM patients studied. We believe Cotara represents a promising experimental therapy for patients with this most deadly form of brain cancer.”

These new interim data are being presented in a poster at the 2010 Congress of Neurological Surgeons (CNS) Annual Meeting in San Francisco, California. The CNS is a world leader in neurosurgical education and innovation with over 7,000 members worldwide. For more information, please visit http://w3.cns.org/meetings/2010/index.asp.

About Peregrine’s Phase II Cotara Trial
Peregrine’s ongoing Phase II open-label trial is enrolling up to 40 GBM patients at first relapse at sites in the U.S. and India. The primary endpoint is safety and tolerability of the maximum tolerated dose, a single 25-hour interstitial infusion of 2.5 mCi/cc of Cotara. Secondary endpoints include overall survival, progression free survival, and proportion of patients alive at six months after treatments. For additional information, please visit http://clinicaltrials.gov/ct2/show/NCT00677716?term=cotara&rank=1.

About Cotara
Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara’s targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain.

About Brain Cancer
According to the American Cancer Society, in 2010 there will be an estimated 22,000 malignant tumors diagnosed and approximately 13,000 deaths attributed to brain or spinal cord cancer in the United States. The most common type of brain cancer is glioblastoma multiforme (GBM), which accounts for 60% of all malignant brain cancers. An aggressive form of cancer, GBM is the deadliest form of brain cancer, with a five-year survival rate of only 3%. Currently approved therapies include Temodar® (temozolomide) and Avastin® (bevacizumab), both of which have modest effect on patient survival.

About All-India Institute of Medical Sciences
One of the most prestigious medical colleges in India, All-India Institute of Medical Sciences (AIIMS) was established as an institution of national importance by an act of the Indian Parliament. With comprehensive facilities for teaching, research, and patient care, AIIMS’ objective is to provide a high standard of medical education and training in India.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that interim results may not be indicative of final results and patient enrollment may be delayed and the risk that the company may not have the financial resources to conduct a registration trial for Cotara. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2010 and quarterly report on Form 10-Q for the quarter ended July 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contact:
Amy Figueroa
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

ADA-ES (ADES) Reports on First Quarter of CyClean Operations

Oct. 18, 2010 (Business Wire) — ADA-ES, Inc. (NASDAQ: ADES) (“ADA”) today announced that the two refined coal facilities leased through Clean Coal Solutions, LLC (“CCS”), its joint venture with NexGen Refined Coal, LLC (“NexGen”), an affiliate of NexGen Resources Corporation, have completed their first quarter of operation. Even with startup issues typical of new technologies at power plants, sufficient Refined Coal was produced and sold during the third quarter to generate in excess of $3 million in revenue for ADA.

In the latter half of the third quarter, the facilities ramped up production to expected continuous levels and are now treating over 95% of the available coal used by the four generating units at the two power plants. These production levels are expected to generate over $15 million per year in revenues and, after deduction of NexGen’s 50% share, over $7 million in pre-tax cash flow and operating income, or nearly $1.00 per share annually, for ADA through 2019.

CCS signed agreements with a large financial institution at the end of June 2010 to lease the two CyClean facilities. They produce Refined Coal that is intended to qualify for Section 45 tax credits. The two systems are installed at two different power plants in the Midwest each of which operates two cyclone boilers burning Powder River Basin (“PRB”) coal from Wyoming. With all four boilers operating, the units are expected to burn approximately 6 million tons of Refined Coal per year that will qualify for the approximately $6.20 per ton of federal tax credits, which escalate annually and are available for the next ten years.

The leases of the two CyClean facilities also provided for a $9 million cash payment to CCS for Pre-paid Rent in addition to future Fixed and Contingent Rent payments that are expected to generate in excess of $2.00 per ton of operating income to CCS over the terms of the leases. These installations triggered up to $4 million in payment obligations of NexGen to ADA for NexGen to maintain its 50% ownership of CCS. Such payments are being made out of CCS’s cash distributions to NexGen.

Mike Durham, ADA’s President and CEO, stated, “With the rapid ramp up of these two systems, we are now closely mirroring the operations of the power plants. We expect these systems to provide significant cash flows for ADA over the next ten years. In addition, they enable us to provide a power generating customer with economic benefits resulting from the use of our proprietary technology, including increased fuel flexibility, decreased operating costs, and decreased emissions of NOx and mercury.”

About ADA-ES

ADA-ES is a leader in clean coal technology and associated specialty chemicals, serving U.S. and Canadian plants that burn coal and other industrial facilities. Our proprietary environmental technologies and specialty chemicals enable those plants to enhance existing air pollution control equipment, minimize mercury, CO₂ and other emissions, maximize capacity, and improve operating efficiencies, to meet the challenges of existing and pending emission control regulations.

With respect to mercury emissions:

• We supply activated carbon (“AC”) injection systems, mercury measurement instrumentation, and related services.
• We are also a joint venture participant in ADA Carbon Solutions (“ADA-CS”), which has commenced operations on its state-of-the-art AC production facility.
• Under an exclusive development and licensing agreement with Arch Coal, we are developing and commercializing an enhanced Powder River Basin (“PRB”) coal with reduced emissions of mercury and other metals.
• Through our consolidated subsidiary, Clean Coal Solutions, LLC (“CCS”), we provide our patented refined coal technology, CyClean, to enhance combustion of and reduce emissions from burning PRB coals in cyclone boilers.

In addition, we are developing CO₂ emissions technologies under projects funded by the U.S. Department of Energy (“DOE”) and industry participants.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, which provides a “safe harbor” for such statements in certain circumstances. The forward-looking statements are statements regarding the amount and timing of future tax credits, revenues, operating income and cash flow; production levels; and qualification of our Refined Coal for the tax credits. These statements are based on current expectations, estimates, projections, beliefs and assumptions of our management. Such statements involve significant risks and uncertainties. Actual events or results could differ materially from those discussed in the forward-looking statements as a result of various factors, including but not limited to, changes in laws and regulations, costs and economic conditions; technical and operational difficulties; failure of CCS’ leased facilities to continue to produce Refined Coal that qualifies for the tax credits; termination of the leases for such facilities; decreases in the production of Refined Coal by the lessee of such facilities due to decreased demand for electricity, planned or unplanned outages or other reasons; availability of raw materials and equipment; loss of key personnel; and other factors discussed in greater detail in our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on our forward-looking statements and to consult filings we make with the SEC for additional risks and uncertainties that may apply to our business and the ownership of our securities. Our forward-looking statements are presented as of the date made, and we disclaim any duty to update such statements unless required by law to do so.

ADA-ES, Inc.

Mark H. McKinnies, CFO, 303-734-1727

www.adaes.com

or

Investor Relations Counsel

The Equity Group Inc.

www.theequitygroup.com

Melissa Dixon, 212-836-9613

MDixon@equityny.com

Linda Latman, 212-836-9609

LLatman@equityny.com

YRC Worldwide (YRCWD) Provides Third Quarter Update

OVERLAND PARK, Kan. — YRC Worldwide Inc. (Nasdaq: YRCWD) today provided an update on its expected third quarter results including:

• For the third quarter of 2010, tonnage per day for YRC National and YRC Regional was 1.2% and 2.1%, respectively, higher than the tonnage per day for the second quarter of 2010. Revenue per shipment during the third quarter of 2010 for YRC National and YRC Regional was 1.9% and 3.7%, respectively, higher than the third quarter of 2009.
• The company expects third quarter 2010 positive adjusted EBITDA within a range of $42 million to $46 million. For the second and third quarters of 2010, the company expects cumulative adjusted EBITDA within a range of $82 million to $86 million, which exceeds the $50 million covenant level required by its credit agreement. The company expects a third quarter 2010 operating loss within a range of $18 million to $22 million. As a comparison, the company reported an operating loss of approximately $35 million for the second quarter of 2010 when excluding an $83 million non-cash benefit from an adjustment to the fair value of the March 2010 union employee equity award.
• At September 30, 2010, the company’s estimated cash and cash equivalents were $115 million, restricted revolver reserves were $123 million, and unrestricted availability was $46 million, for a total of $284 million. During the third quarter of 2010 the company repaid $25 million of outstanding borrowings on its asset-backed securitization facility.

Third Quarter Earnings Call

The company will hold a conference call for the investment community on Friday, November 5, 2010, beginning at 9:30am ET, 8:30am CT.  Third quarter earnings will be released the same day, Friday, November 5, 2010, prior to the opening of the market. The conference call will be open to listeners live and by recorded playback via the YRC Worldwide Internet site yrcw.com.

Certain Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP measure that reflects the company’s earnings before interest, taxes, depreciation, and amortization expense, and further adjusted for letter of credit fees, equity-based compensation expense, net gains or losses on property disposals and certain other items as defined in the company’s credit agreement. Operating loss, as adjusted, is a non-GAAP measure that excludes a non-cash benefit from an adjustment to the fair value of the March 2010 union employee equity award.  Adjusted EBITDA and operating loss, as adjusted, are used for internal management purposes as financial measures that reflect the company’s core operating performance. In addition, management uses adjusted EBITDA to measure compliance with financial covenants in the company’s credit agreement. However, these financial measures should not be construed as a better measurement than operating income (loss) or earnings per share, as defined by GAAP.

Adjusted EBITDA has the following limitations:

• Adjusted EBITDA does not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our outstanding debt;
• Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted EBITDA does not reflect any cash requirements for such replacements;
• Equity-based compensation is an element of our long-term incentive compensation program, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period; and
• Other companies in our industry may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Because of these limitations, adjusted EBITDA should not be considered a substitute for performance measures calculated in accordance with GAAP.

Reconciliation of GAAP Measures to Non-GAAP Financial Measures

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “expects,” “expected,” “estimated,” and similar expressions are intended to identify forward-looking statements. It is important to note that the company’s actual future results could differ materially from those projected in such forward-looking statements because of a number of factors, including (among others) our ability to generate sufficient cash flows and liquidity to fund operations, which raises substantial doubt about our ability to continue as a going concern, inflation, inclement weather, price and availability of fuel, sudden changes in the cost of fuel or the index upon which the company bases its fuel surcharge, competitor pricing activity, expense volatility, including (without limitation) expense volatility due to changes in rail service or pricing for rail service, ability to capture cost reductions, changes in equity and debt markets, a downturn in general or regional economic activity, effects of a terrorist attack, labor relations, including (without limitation), the impact of work rules, work stoppages, strikes or other disruptions, any obligations to multi-employer health, welfare and pension plans, wage requirements and employee satisfaction, and the risk factors that are from time to time included in the company’s reports filed with the SEC.

The company’s expectations regarding financial information related to third quarter 2010 are only its expectations regarding these matters.  Actual financial information for third quarter 2010 could differ based on a number of factors including (among others) any adjustments or final entries necessary to close the company’s books for third quarter 2010.

The company’s expectations regarding its cash and cash equivalents are only its expectations regarding this matter.  The actual cash and cash equivalents could differ based on a number of factors including (among others) the company’s operating results, the timing of its receipts and disbursements, the company’s access to credit facilities or credit markets and the factors identified in the preceding paragraphs.

About YRC Worldwide

YRC Worldwide Inc., a Fortune 500 company headquartered in Overland Park, Kan., is a leading provider of transportation and global logistics services. It is the holding company for a portfolio of successful brands including YRC, YRC Reimer, YRC Glen Moore, Reddaway, Holland and New Penn, and provides China-based services through its Jiayu and JHJ joint ventures. YRC Worldwide has the largest, most comprehensive network in North America with local, regional, national and international capabilities. Through its team of experienced service professionals, YRC Worldwide offers industry-leading expertise in heavyweight shipments and flexible supply chain solutions, ensuring customers can ship industrial, commercial and retail goods with confidence. Please visit www.yrcw.com for more information.

Rock of Ages (ROAC) Announces $5.25 Per Share Cash Merger Agreement with Swenson Granite

Oct. 18, 2010 (Business Wire) — Rock of Ages Corporation (NASDAQ:ROAC) today announced that it has entered into a definitive merger agreement with Swenson Granite Company LLC (“Swenson Granite”) whereby shareholders of Rock of Ages will receive $5.25 per share in cash, and Swenson Granite will acquire 100% ownership of Rock of Ages.

The Rock of Ages Board of Directors, based in part on the unanimous recommendation of a special committee of three Rock of Ages independent directors, unanimously adopted, and recommends that shareholders of the Company vote for approval of, the merger agreement. The special committee’s independent financial advisor has delivered an opinion to the effect that the $5.25 per share to be received by Rock of Ages shareholders in the merger is fair, from a financial point of view, to such shareholders. The $5.25 per share price represents a 57% premium to the average closing price of Rock of Ages Class A common stock for the 30 days prior to the May 7, 2010 announcement of Swenson Granite’s initial proposal to acquire 100% ownership of Rock of Ages, and a 84% premium to the average closing price for the 12 months prior to the May 7, 2010 announcement.

Consummation of the merger is conditioned upon, in addition to approval of the merger agreement by the majority vote of Rock of Ages’ Class A and Class B common stock, voting together, approval by a majority of the outstanding shares of Class A common stock, excluding shares held by members of Swenson Granite. Rock of Ages will schedule a special meeting of its shareholders for the purpose of obtaining shareholder approval of the merger agreement.

Kurt Swenson, the Chairman of Swenson Granite and non-executive Chairman of Rock of Ages, together with his brother, Kevin Swenson, Vice President of Swenson Granite, and Robert Pope, President and Chief Executive Officer of Swenson Granite, own approximately 71% of Swenson Granite. They, along with certain other members of Swenson Granite who are also Rock of Ages shareholders, have agreed with Swenson Granite to vote their shares, representing approximately 81% of the total voting power of all Rock of Ages shares, in favor of approval of the merger agreement.

The merger agreement includes various other customary conditions, but does not contain a financing condition. People’s United Bank and Key Bank, National Association have committed, subject to customary conditions, to provide debt financing for the transaction.

Prior to the merger, Kurt Swenson, Kevin Swenson, Robert Pope and certain other members of Swenson Granite who are also shareholders of Rock of Ages, will contribute to Swenson Granite a total of 258,326 Class A shares and 2,449,793 Class B shares of Rock of Ages in exchange for additional shares of membership interest in Swenson Granite, and will not receive the $5.25 per share cash merger price for those Rock of Ages shares.

Covington Associates, LLC served as financial advisor to the special committee of the Rock of Ages board of directors and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to the special committee. Sheehan Phinney Bass + Green PA served as legal counsel to Swenson Granite.

About Rock of Ages

Rock of Ages (www.RockofAges.com) is the largest integrated granite quarrier and manufacturer of finished granite memorials and granite blocks for memorial use in North America.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations about future events. These statements are not guarantees of future events and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual events may differ materially from what is expressed in such forward-looking statements due to numerous factors. A statement containing an expectation or prediction as to the consummation of the merger is just an example of a forward-looking statement. Some factors that could realistically cause events to differ materially from those predicted in the forward-looking statements include the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with Swenson Granite Company LLC (“Swenson Granite”); the outcome of any legal proceedings that have been, or may be, instituted against Rock of Ages related to the merger agreement; the inability to complete the merger due to the failure to obtain shareholder approval for the merger or the failure to satisfy other conditions to completion of the merger; and the failure of Swenson Granite to obtain the necessary financing arrangements relating to the merger. Further information and risks regarding factors that could affect our business, operations, financial results or financial positions are discussed from time to time in Rock of Ages’ Securities and Exchange Commission filings and reports. Such forward-looking statements speak only as of the date on which they are made, and Rock of Ages does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release, except as may be required under the federal securities laws.

About the Proposed Transaction

In connection with the proposed merger, Rock of Ages will file a proxy statement with the Securities and Exchange Commission. INVESTORS AND SECURITY HOLDERS ARE STRONGLY ADVISED TO READ THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain a free copy of the proxy statement (when available) and other documents filed by Rock of Ages from the Securities and Exchange Commission’s Web site at http://www.sec.gov. The proxy statement and such other documents may also be obtained for free from Rock of Ages’ website at http://www.rockofages.com or by directing such request to Rock of Ages Corporation, Chief Financial Officer, 560 Graniteville Road, Graniteville, Vermont 05654, telephone: (802) 476-3115.

Rock of Ages and its directors, executive officers and certain other members of its management and employees may be deemed to be participants in the solicitation of proxies from its shareholders in connection with the proposed merger. Information regarding the interests of Rock of Ages’ participants in the solicitation will be included in the proxy statement relating to the proposed merger when it becomes available. Additional information regarding Rock of Ages’ directors and executive officers is also included in Rock of Ages’ proxy statement for its 2010 Annual Meeting of Stockholders, which was filed with the SEC on July 19, 2010. This document is available free of charge from the SEC’s Web site at www.sec.gov, from Rock of Ages’ website at http://www.rockofages.com or by directing such request to Rock of Ages Corporation, Chief Financial Officer, 560 Graniteville Road, Graniteville, Vermont 05654, telephone: (802) 476-3115.

Rock of Ages Corporation

Laura A. Plude, 802-476-2208

Chief Financial Officer

www.RockofAges.com

St. Jude Medical (STJ) and AGA Medical (AGAM) Announce Definitive Agreement

Oct. 18, 2010 (Business Wire) — St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, and AGA Medical Holdings, Inc. (Nasdaq:AGAM), today announced that the Boards of Directors of both companies have approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of AGA Medical for $20.80 per share in a cash and stock transaction valued at approximately $1.3 billion, including the assumption of approximately $225 million in outstanding debt. The transaction is expected to be conducted as an exchange offer followed by a merger and to close by the end of the year.

AGA Medical, with sales of approximately $199 million in 2009, is a global innovator and manufacturer of a comprehensive line of devices used to treat structural heart defects and vascular abnormalities through minimally invasive transcatheter treatments. The combination of the complementary product lines of St. Jude Medical and AGA Medical will create a clear leader in the structural heart market, making St. Jude Medical the only company with programs across all major categories that include structural heart defects, left atrial appendage occlusion, transcatheter aortic valve implantation and percutaneous mitral valve repair.

The acquisition represents a significant addition to St. Jude Medical’s cardiovascular and atrial fibrillation growth programs, adding to the company’s portfolio a leading position in four new markets – the market for left atrial appendage (LAA) closure, the market for patent foramen ovale (PFO) closure in cryptogenic stroke patients, the market to modify abnormal peripheral vessels with vascular plugs and the market to repair structural heart defects. AGA Medical’s revenue has grown at a compounded annual rate of 19 percent during the period from 2005 to 2009. On a constant currency basis, St. Jude Medical expects AGA Medical to grow its revenue in the low double-digits for 2011, not including the benefits of any possible future product approvals or successful clinical trial outcomes.

AGA Medical’s AMPLATZER® device platform has strong brand-name recognition for its clinical excellence and ease of use. The company’s occlusion (closing or sealing) devices offer minimally invasive transcatheter treatments clinically proven to be safe and effective in closing structural defects found in a patient’s heart. Its portfolio of vascular plugs has the potential to change the standard of care for the treatment of peripheral abnormal blood vessels. AGA Medical’s AMPLATZER devices are currently marketed and sold in 112 countries and more than 450,000 AGA Medical products have been sold worldwide.

“St. Jude Medical believes that the acquisition of AGA Medical will benefit customers, employees and shareholders of both companies,” said Daniel J. Starks, Chairman, President and Chief Executive Officer of St. Jude Medical. “AGA Medical has developed technologies with proven clinical outcomes. It has a strong core business with an enviable pipeline of products and clinical trials. We look forward to AGA Medical employees joining St. Jude Medical and to the further development of these programs.”

“In St. Jude Medical we have found a partner that shares our commitment to develop innovative products that support the vision, leadership and innovation of our co-founder, Dr. Kurt Amplatz, whose ground-breaking devices have improved the lives of patients around the world, and with whom we look forward to continuing to work in the future,” said John Barr, President and Chief Executive Officer of AGA Medical. “We are very pleased to be joining St. Jude Medical, which – through its geographic scale, expertise and resources – will help us expand the reach of our products both geographically and across physician specialties.”

Following the completion of the transaction, AGA Medical will become part of St. Jude Medical’s Cardiovascular Division. AGA Medical President and CEO John Barr has agreed to join St. Jude Medical, reporting to Cardiovascular Division President Frank Callaghan. St. Jude Medical plans to continue operations from AGA Medical’s current location in Plymouth, Minn.

Terms of the Agreement

Under the terms of the definitive agreement, AGA Medical shareholders will receive $20.80 for each share of AGA Medical stock they own in the form of cash and/or St. Jude Medical common stock. The split between cash and stock consideration will be 50 percent of each. Holders of AGA Medical stock tendered in the exchange offer may elect to receive cash or shares of St. Jude Medical common stock, subject to proration and adjustment pursuant to the definitive agreement. Under the terms of the agreement, the exchange ratio for the stock component will be determined based on the average closing price of St. Jude Medical common stock over 10 trading days ending two days prior to the close of the exchange offer. Upon consummation of the exchange offer, St. Jude Medical intends to complete a merger in order to acquire all the shares of AGA Medical common stock that remain outstanding after the completion of the exchange offer.

St. Jude Medical intends to commence an exchange offer for all of the outstanding shares of AGA Medical on or around October 20, 2010, which will remain open for at least 20 business days. Major shareholders, including certain shareholders affiliated with Welsh Carson Anderson & Stowe, holding approximately 44 percent of AGA Medical’s outstanding common stock and AGA Medical’s co-founder Franck Gougeon, holding approximately 19 percent of AGA Medical’s outstanding common stock, have confirmed their intention to tender all of their shares into the offer.

St. Jude Medical will use cash on hand to fund the cash portion of the consideration. Except for one-time acquisition-related expenses expected to be recorded in the fourth quarter, this acquisition does not impact St. Jude Medical’s outlook for 2010 consolidated earnings per share. In addition, in connection with this transaction, the St. Jude Medical Board of Directors has approved a stock repurchase authorization of up to $600 million of St. Jude Medical common stock to offset the shares issued in this transaction, subject to market conditions.

The transaction is subject to customary closing conditions and regulatory approvals, as well as the valid tender of a majority of the outstanding shares of AGA Medical common stock in the exchange offer, on a fully-diluted basis. St. Jude Medical expects the transaction to close by the end of the year.

Strategic and Financial Benefits

The acquisition of AGA Medical is highly complementary to the St. Jude Medical business and enables St. Jude Medical to extend its product reach into new areas.

• Clear structural heart leader: AGA Medical is the market share leader in structural heart defect occluders, and when combined, the two companies will have programs across all major categories that include structural heart defects, left atrial appendage occlusion, transcatheter aortic valve implantation and percutaneous mitral valve repair.
• Complementary programs: AGA Medical’s experience with products that use nitinol braiding have allowed the company to recently expand into the vascular market served by interventional radiologists and vascular surgeons, which will add growth and extend St. Jude Medical’s vascular closure franchise into this market. Additionally, St. Jude Medical’s leading electrophysiology and cardiovascular franchise can benefit AGA Medical’s emerging products for occlusion of the LAA, an area that has the potential to become a major new growth driver for St. Jude Medical over the next five years as part of the company’s atrial fibrillation and structural heart programs.
• International growth: St. Jude Medical’s global presence can further strengthen and enhance AGA Medical’s international growth. While 60 percent of AGA Medical’s sales come from international markets, only 20 percent of its sales are generated from markets outside of Europe. St. Jude Medical’s geographic distribution scale can accelerate AGA Medical’s growth more rapidly in numerous markets.
• Market potential: There are also a number of opportunities for AGA Medical’s occlusion devices to expand the existing structural heart market. AGA Medical currently has four randomized, prospective clinical trials underway to explore new geographic approvals and expanded indications for products that are already manufactured and sold outside of the U.S. Three of these trials are focused on a type of structural heart defect known as a PFO – a hole in the wall between the left and right atria – and its relationship to both stroke and migraine.
  • The RESPECT clinical trial in the U.S. is investigating whether PFO closure with the AMPLATZER® PFO Occluder is safe and effective in preventing recurrent cryptogenic strokes (those of an unknown origin).
  • The PREMIUM clinical trial in the U.S. is evaluating whether PFO closure with the AMPLATZER PFO Occluder is an effective treatment for certain types of migraine patients.
  • The PRIMA clinical trial is an international trial evaluating whether PFO closure with the AMPLATZER® PFO Occluder is an effective treatment for certain types of migraine patients.
  • A fourth clinical trial is studying the AMPLATZER® Cardiac Plug (ACP) for the LAA, which brings new growth opportunities for St. Jude Medical’s atrial fibrillation and cardiology product platforms. AGA Medical is in the feasibility phase of a U.S. clinical trial that is designed to evaluate the use of the ACP to prevent stroke in atrial fibrillation patients.
• Accretive transaction: AGA Medical has experienced strong revenue growth with historically strong gross margins. The transaction is expected to be accretive to earnings in 2011 and beyond on a GAAP basis, excluding the increase to cost of goods sold related to the step up in inventory values required under purchase accounting. St. Jude Medical expects to record a non-recurring transaction-related charge in the fourth quarter of 2010.

In connection with this transaction, BofA Merrill Lynch is acting as financial advisor and Gibson, Dunn & Crutcher LLP as legal advisor to St. Jude Medical. Piper Jaffray & Co. is acting as financial advisor and Fredrikson & Byron, P.A. as legal counsel to AGA Medical.

Conference Call and Webcast

St. Jude Medical will hold its regular quarterly earnings conference call and webcast for investors and analysts on Wednesday, Oct. 20, 2010, at 8 a.m. EDT (7 a.m. CDT) where management will also discuss this transaction. This call is being webcast by Thomson Reuters and can be accessed live at the St. Jude Medical Investor Relations website (www.sjm.com/corporate/investor-relations.aspx), where it will also be archived for 90 days.

About AGA Medical

AGA Medical, based in Plymouth, Minn., is a leading innovator and manufacturer of medical devices for the treatment of structural heart defects and vascular abnormalities. AGA Medical’s AMPLATZER® occlusion devices offer minimally invasive transcatheter treatments that have been clinically proven to be safe and highly effective in defect closure. AGA Medical is the only manufacturer with occlusion devices approved to close seven different structural heart defects, with leading market positions for each of its devices. More than 1,650 articles supporting the benefits of AMPLATZER® products have been published in medical literature. AGA Medical markets its AMPLATZER® products in 112 countries worldwide to interventional cardiologists, electrophysiologists, interventional radiologists and vascular surgeons. More information about the company and its products can be found at http://www.amplatzer.com.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expected structure and timetable for the transaction between St. Jude Medical and AGA Medical, the transaction’s anticipated strategic and financial benefits, revenues and earnings guidance for St. Jude Medical and AGA Medical, and expectations regarding AGA Medical’s ongoing operations, employees and consultants following the transaction. The statements made by AGA Medical and St. Jude Medical in this release are based upon current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act and the tender of a majority of the outstanding shares of common stock of AGA Medical; market conditions; the effect of the announcement of the merger on St. Jude Medical’s and AGA Medical’s respective business; the impact of any failure to complete the exchange offer and the merger; the risk that St. Jude Medical will not realize the anticipated benefits of the acquisition; the potential inability to successfully operate or integrate AGA Medical’s business; general industry and economic conditions; and other factors beyond the companies’ control and the risk factors and other cautionary statements described in the St. Jude Medical’s and AGA Medical’s filings with the SEC. Please refer to the Risk Factors and Cautionary Statements sections of St. Jude Medical’s Quarterly Report on Form 10-Q for the fiscal quarter ended April 3, 2010, and the Risk Factors set forth in AGA Medical’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2010, for a further list and description of additional business risks, uncertainties, and other factors that may affect these statements. Neither St. Jude Medical nor AGA Medical intends to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Important Additional Information

The exchange offer for the outstanding shares of common stock of AGA Medical has not yet commenced. This press release is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell shares of common stock of AGA Medical, nor is it a substitute for the registration statement and tender offer materials that St. Jude Medical will file with the Securities and Exchange Commission upon commencement of the tender offer.

Investors and security holders of AGA Medical are urged to read the tender offer statement on Schedule TO and the registration statement on Form S-4, to be filed by St. Jude Medical with the SEC upon commencement of the exchange offer, and the solicitation/recommendation statement on Schedule 14d-9 regarding the exchange offer, which will be filed by AGA Medical with the SEC upon the commencement of the exchange offer. The tender offer materials (including an offer to purchase, letter of transmittal and related tender offer documents) and the solicitation/recommendation statement will contain important information which should be read carefully before any decisions are made with respect to the offer.

In addition to the tender offer statement, the solicitation/recommendation statement and the registration statement described above, AGA Medical and St. Jude Medical file annual, quarterly and current reports, proxy statements and other information with the SEC. The tender offer statement, the solicitation/recommendation statement, the registration statement and any other relevant materials, when they become available, and any other documents filed with the SEC by AGA Medical or St. Jude Medical, are available without charge at the SEC’s website at www.sec.gov, or from the companies’ websites, at www.amplatzer.com and www.sjm.com, respectively.

Neither St. Jude Medical nor AGA Medical is asking for your vote or soliciting proxies in connection with the transaction at this time. Upon consummation of the exchange offer, St. Jude Medical and AGA may seek votes or proxies in connection with the proposed back-end merger from holders of AGA shares not tendered in the exchange offer. AGA Medical, St. Jude Medical and their respective officers and directors may be therefore deemed to be participants in the solicitation of proxies from AGA Medical’s shareholders in connection with the proposed merger. A description of certain interests of the directors and executive officers of AGA Medical is set forth in AGA Medical’s proxy statement for its 2010 annual meeting, which was filed with the SEC on April 29, 2010. A description of certain interests of the directors and executive officers of the St. Jude Medical is set forth in the St. Jude Medical’s proxy statement for its 2010 annual meeting, which was filed with the SEC on March 23, 2010. Additional information regarding the interests of such potential participants will be included in the registration statement and other relevant documents to be filed with the SEC in connection with the proposed merger.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6470791&lang=en

St. Jude Medical

Angela Craig, 651-756-2191

acraig@sjm.com

or

AGA Medical

Rachel Ellingson, 763-531-3018

rellingson@amplatzer.com

Kibbutz Shamir (SHMR)and Essilor Sign Agreement

KIBBUTZ SHAMIR, Israel and CHARENTON-LE-PONT, France, Oct. 15 /PRNewswire-FirstCall/ — Shamir Optical Industry Ltd. (Nasdaq:SHMR – News) (“Shamir Optical”), Kibbutz Shamir and Essilor International (NYSE Euronext: EI) (“Essilor”) today announced that they have signed an agreement whereby Essilor will, through a series of transactions, acquire 50% of Shamir Optical. As a result of these transactions, Kibbutz Shamir and Essilor will each own 50% of Shamir Optical.

Headquartered in Kibbutz Shamir, Israel, Shamir Optical is a fast growing provider of innovative products and technology to the ophthalmic lens industry. Shamir Optical reported 2009 revenues of $142 million, generated mainly in Europe and the United States, and has approximately 1,400 full-time employees.

Amos Netzer, Chief Executive Officer of Shamir Optical commented, “This venture places Shamir Optical in a position to accelerate the development of new products and to strengthen its presence in the market place by using Essilor’s R&D capabilities, notably in coatings, and its worldwide distribution network. The transaction will create synergies and provide Shamir Optical with additional resources to invest in its development.”

Hubert Sagnieres, Essilor’s Chief Executive Officer said, “This joint venture represents a strategic addition to Essilor’s business and will strengthen our offer to the mid-tier segment with additional high-quality products. Shamir Optical’s range of products fits closely with Essilor’s. Thanks to our existing network, respective expertise and the potential for vertical cost synergies, our partnership will allow us to grow the worldwide optical business with innovative, new value-added products and services and to expand our offer to eyecare professionals around the world. Shamir Optical will continue to produce and promote its brands, products and services as a separate business entity.”

Under the planned transaction, Shamir Optical will be delisted from the Nasdaq Global Market and the Tel Aviv Stock Exchange through a merger with a wholly owned subsidiary of Essilor by which all shareholders other than Kibbutz Shamir will receive cash for their shares. Essilor will simultaneously acquire for cash additional shares directly or indirectly from Kibbutz Shamir in order to reach 50% of Shamir Optical. The price offered for each transaction is $14.50 per Shamir Optical share. This price, together with the dividend of $0.804 payable to Shamir Optical shareholders of record on 8th November 2010, represents a total value of $15.30 per share, corresponding to a 57% premium over the last 90 day average closing share price on Nasdaq of $9.75. The transaction will represent a cash investment of $130 million for Essilor, to be fully financed using Essilor’s existing committed credit facilities.

Shamir Optical’s Board of Directors and its Audit Committee have unanimously approved the terms of the proposed transaction and Shamir Optical’s Board of Directors has recommended it to Shamir Optical Shareholders. Certain shareholders representing approximately 69.3% of Shamir Optical’s outstanding capital, including Kibbutz Shamir, have signed support agreements committing to vote in favour of the transaction at the special meeting of shareholders that will be called to approve the transaction.

Under the terms of the agreements between Essilor and Kibbutz Shamir, the existing management team of Shamir Optical will remain in place.

The transaction, which is subject to regulatory approvals, rulings, the approval of Shamir Optical’s shareholders in accordance with Israeli law and the approval of the district court of Nazareth, Israel, is expected to close in mid 2011.

The Merger Agreement contains certain termination rights for both Essilor and Shamir Optical and further provides that, upon termination of the Merger Agreement under specified circumstances, Shamir Optical may be required to pay Essilor termination fees of $11 million.

Shamir Optical expects to send its shareholders a shareholder information statement and proxy materials in connection with the meeting at which Shamir Optical’s shareholders will be asked to approve the proposed merger. Shamir Optical’s shareholders are urged to read the shareholder information statement and proxy materials, when they become available, because they will contain important information (see below, “Where You Can Obtain Further Information”).

Essilor will fully consolidate Shamir Optical upon closing. Based on current estimates, the transaction is expected to be accretive to Essilor’s earnings per share as of 2011 (before impact of the purchase price allocation).

This news release is provided for information purposes only and does not constitute an offer to purchase any security, nor is it a solicitation of any vote or approval in any jurisdiction.

Shareholders of Shamir Optical should be aware that the consummation of the merger proposal is subject to various conditions, including the requisite shareholder vote described above, and therefore the merger proposal may not be consummated. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, attorney or other professional advisers.

Where You Can Obtain Further Information

Details of the merger proposal will be contained in a document (the “Information Statement “) to be mailed to the shareholders of Shamir Optical in due course.  In addition, since the merger proposal constitutes a “going private transaction” subject to the requirements of Rule 13e-3 under the U.S. Securities Exchange Act of 1934, a Schedule 13E-3 will be filed as required with the United States Securities and Exchange Commission (the “SEC”).  All shareholders are urged to read the Schedule 13E-3, the Information Statement and any other definitive materials accompanying those documents before casting any vote at (or providing any proxy for) the special meeting of the shareholders.  Shareholders may obtain such documents free of charge when they are furnished to the SEC and become available at the Web site maintained by the SEC (http://www.sec.gov).

About Shamir Optical

Shamir Optical is a leading provider of innovative products and technology to the spectacle lens market. Shamir Optical’s leading lenses are marketed under a variety of trade names, including Shamir Creation™, Shamir Piccolo™, Shamir Office™, Shamir Autograph™, Shamir Attitude™ and Shamir Smart™. Shamir Optical is one of the world’s preeminent research and development teams for progressive lenses, molds, and complementary technologies and tools. Shamir developed software dedicated to the design of progressive lenses. This software is based on Shamir Optical’s proprietary mathematical algorithms that optimize designs of progressive lenses for a variety of activities and environments. Shamir Optical also has created software tools specifically designed for research and development and production requirements, including Eye Point Technology software, which simulates human vision.

About Essilor

The world leader in ophthalmic optical products, Essilor International researches, develops, manufactures and markets around the world a wide range of lenses to improve and protect eyesight. Its flagship brands are Varilux®, Crizal®, Essilor®, Definity® and Xperio™.

With 34,700 employees and operations in 100 countries, the company reported consolidated revenue of more than euro 3.2 billion in 2009.

The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: (ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP).

For more information, please visit www.essilor.com.

FORWARD LOOKING STATEMENTS – DISCLAIMER AND SAFE HARBOR STATEMENTS

Statements concerning the contemplated merger and related transactions, Shamir Optical’s or Essilor’s business outlook, plans and objectives, product introductions and future economic performance and assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements” as that term is defined under U.S. federal securities laws. Forward-looking statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results or expectations expressed in those statements. These risks, uncertainties and factors include, but are not limited to: the inability to close the transactions referred to in this news release, to obtain required Israeli court approval, regulatory and shareholder approvals of the merger and related transactions, and the performance of the obligations pursuant to the related agreements; conflicts in the region, the effects of competition in the industry, and changes in Shamir Optical’s or Essilor’s relationships with optical laboratories, distributors, research and development partners and other third parties; the effects of the international expansion of operations of Shamir Optical and Essilor, and their ability to manage their growth, including their ability to manage potential future acquisitions; the effect of global economic conditions in general and conditions in the industry and target markets in particular; shifts in supply and demand; market acceptance of new products and continuing products’ demand; the impact of competitive products and pricing, including on products and markets; timely product and technology development/upgrades and the ability to manage changes in market conditions as needed; interest rate fluctuations, liquidity and currency risks, and counterparty and investments risks; other operational, market and legal risks; and other factors detailed in Shamir Optical’s filings with the Securities and Exchange Commission and in Essilor’s annual Registration Document, available on its website (http://www.Essilor.com) (see, in particular, “Risk Factors” in each document). Neither Shamir Optical nor Essilor assume any obligation to update the information in this release.

Nexxus (NEXS) Lighting Receives ENERGY STAR Label for Its Array™ LED Bulb

CHARLOTTE, N.C.–(BUSINESS WIRE)– Nexxus Lighting, Inc. (NASDAQ:NEXS – News) has received the ENERGY STAR label for its 7.8 watt R30 LED light bulb and is now included on the ENERGY STAR Qualified LED Light Bulbs list.

The Array R30 is the first LED reflector lamp replacement that has qualified for the ENERGY STAR label. The R30 underwent rigorous third party testing to specific quality and performance standards to receive the right to use the label.

The R30 utilizes the company’s patented design and patent – pending thermal management system to deliver over 60 lumens per watt. The R30 uses only 8 watts to produce 500 lumens at a color rich 3000° Kelvin color temperature with a color rendering index of 84.

Additional lamps have been submitted by Nexxus to ENERGY STAR as part of an ongoing process by Nexxus to bring industry leading, high quality, commercial grade LED replacement lamps to market.

With 23 issued patents and 37 combined U.S. and foreign patent applications pending related to its Array Lighting product offering, the value proposition created by Nexxus’ innovative patent pending Selective Heat Sink (SHS) technology and patented designs provides the market with opportunities for significant savings in energy and maintenance costs without compromising the environment.

Nexxus Lighting (www.nexxuslighting.com) is a leader in advanced lighting technology, including solid-state LED and fiber optic lighting systems and controls used in commercial, architectural, signage, swimming pool, entertainment and retail lighting. Nexxus Lighting sells its products through its Commercial Lighting, Lumificient and Nexxus Lighting Pool & Spa divisions under the Array™ Lighting, Savi®, eLum™, LiveLED™, Super Vision® and Lumificient™ brand names.

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made to Nexxus Lighting’s filings under the Securities Exchange Act for factors that could cause actual results to differ materially. Nexxus Lighting undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors. Readers are cautioned not to place undue reliance on these forward-looking statements.

Parlux (PARL) Annual Meeting Results

FORT LAUDERDALE, Fla., Oct. 15, 2010 (GLOBE NEWSWIRE) — Parlux Fragrances, Inc. (Nasdaq:PARL – News) held its annual meeting of shareholders (Annual Meeting) on October 12, 2010, in Ft. Lauderdale, FL. At the Annual Meeting, the Company’s shareholders approved two proposals. The proposals are described in detail in the Company’s definitive proxy statement in Schedule 14A filed with the Securities and Exchange Commission on September 7, 2010.

The final voting results with respect to each proposal voted upon at the Annual Meeting are set forth below.

All five nominees named in the proxy statement were elected with each director receiving votes as follows:

There were no abstentions in the election of directors.

The ratification of our current independent auditors, MarcumRachlin, a division of Marcum LLP, was approved by our stockholders as follows:

During the course of the meeting, Mr. Purches, Chairman and CEO, noted that: “For the current fiscal year of 2011, we are forecasting lower net sales than the previous comparable year. If we eliminate our expired license, GUESS, from the prior year we anticipate an increase of approximately 15% to approximately $125 million in net sales in the current year. Keeping our focus on profitability, we have cut back new product launches, and advertising/promotional spending, which was reduced by 35% this current year. We expect to return to profitability this year.”

Mr. Purches added: “It is worth noting that our first six months’ net sales ending September 30, 2010 are expected to be approximately $62 million, compared to approximately $80 million in the comparative prior year. This is significant when one considers that the prior year figures include $28 million of GUESS sales. Paris Hilton and Jessica Simpson products accounted for approximately 80% of our gross revenues for the first six months of the current year. We anticipate this ratio will decrease as we introduce new products later this year and into next year, most notably Rihanna in Spring 2011 and Vince Camuto in Fall 2011. With these new introductions we expect to grow the Company’s revenues, profitability, anticipating net sales of approximately $150 million in fiscal 2012.“

ABOUT PARLUX FRAGRANCES, INC.

Parlux Fragrances, Inc. is a manufacturer and international distributor of prestige products. It holds licenses for Paris Hilton, Jessica Simpson, Nicole Miller, Josie Natori, Queen Latifah, Marc Ecko, Rihanna, Kanye West, babyGund, and Fred Hayman Beverly Hills designer fragrances, as well as Paris Hilton watches, cosmetics, sunglasses, handbags and other small leather accessories, and the recently signed Vince Camuto.

Certain Information Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our plans, strategies and prospects, both business and financial. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company or its industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, future trends in sales and net income, the Company’s ability to maintain its current brands and licenses, the Company’s ability to successfully introduce, acquire, or launch new brands, licenses, or products in a cost-effective manner, general economic conditions, Perfumania’s ability to pay its balance due to the Company, and compliance with the covenants in the Company’s credit facility. Additional risk factors are set forth in the Company’s periodic reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Rentech’s (RTK) Synthetic RenDiesel® Fuels Audi A3 TDIs for 1,000 Mile California Drive

LOS ANGELES–(BUSINESS WIRE)– Rentech, Inc. (NYSE AMEX: RTK) today announced that its synthetic RenDiesel^® will fuel two Audi A3 TDIs during a four day, 1,000 mile journey beginning October 18^th. The Audi A3 TDI^® is Green Car Journal’s 2010 Green Car of the Year^®.

The clean diesel journey by Green Car Journal editors and invited VIPs is part of the magazine’s Green Car of the Year Tour^™, which this year focuses on the important role advanced clean diesel vehicles play in efficiency and CO₂ reduction as well as the importance of sustainable non-petroleum fuels in America’s future.

The two Audi A3 TDIs will run exclusively on RenDiesel® during the ‘Eureka! Diesel Driving the Future’ 1,000-mile journey. The tour will span the state of California, beginning in Eureka and ending in San Diego. Throughout the journey, press conferences will take place in Sacramento (October 19th), Rialto and San Diego (both on October 20th) and at the Petersen Automotive Museum in Los Angeles for a Green Car of the Year Tour™ celebration event (October 21st) at the end of the journey.

“Rentech is excited to participate in this Green Car Journal drive, celebrating innovation and clean diesel,” commented D. Hunt Ramsbottom, President and CEO of Rentech. “Diesel vehicles such as the Audi A3 TDI and fuel such as Rentech’s synthetic drop-in RenDiesel^® provide viable solutions to improving our environment. We commend the Green Car Journal for recognizing innovative technologies and embracing the future of America’s fuels,” Mr. Ramsbottom added.

“When you combine the reigning Green Car of the Year, our Audi A3 TDI, with advanced fuels, such as RenDiesel^®, you begin to see that the future for sustainable motoring is near at hand,” said Johan de Nysschen, President, Audi of America. “These technologies have powerful near-term potential to answer some of our thorniest energy questions.”

The event in Rialto, home to Rentech’s proposed Rialto Renewable Energy Center (Rialto Project), will commemorate the City as “The Chosen City for America’s New Fuels.” The Rialto Project, which is anticipated to create over 1,000 direct and indirect jobs during the construction and operations phases, is designed to produce approximately 640 barrels per day of renewable synthetic fuels, primarily RenDiesel^®_, and approximately 35 MW of renewable electric power (RenPower^TM) from urban green waste diverted from landfills. Both of these products will have low carbon footprints and help California reduce greenhouse gas (GHG) emissions, consistent with the State’s Low Carbon Fuel Standard and Renewable Portfolio Standard. The project is a candidate for a U.S. Department of Energy loan guarantee.

Rentech’s synthetic RenDiesel^® can be produced from a variety of domestic resources using the Company’s proprietary technologies to create sustainable and environmentally friendly diesel fuel. RenDiesel^® is biodegradable, exceeds all global sulfur requirements and has virtually no aromatics. When compared to traditional petroleum-derived low sulfur diesel, tailpipe emissions from RenDiesel^® generate lower amounts of hydrocarbons, carbon monoxide, particulate matter, nitrogen oxides (NO_X), sulfur oxides (SO_X) and carbon dioxide. Also, when compared to traditional diesel fuels, RenDiesel^® has higher hydrogen content, heating value and cetane index, making it very energy-efficient.

RenDiesel^® provides a viable solution that can be deployed today to minimize the transportation sector’s environmental impact. The renewable RenDiesel^® to be produced at the Rialto Project is expected to reduce greenhouse gas emissions on a lifecycle basis by as much as 97% over conventional diesel fuel and by a comparable amount over electric vehicles. A vehicle using RenDiesel^® is also expected to be as much as two times more fuel efficient than one running on ethanol. RenDiesel^® contains approximately 60% more energy per gallon than ethanol and diesel engines typically achieve 20-40% more miles per gallon than gasoline engines. RenDiesel^® also produces fewer volatile organic compound (VOC) emissions than ethanol or traditional diesel.

The celebratory conclusion of the ‘Eureka! Diesel Driving the Future’ 1,000-mile journey will include a clean diesel panel discussion at the Peterson Automotive Museum in Los Angeles. The panel will be moderated by Green Car Journal’s Ron Cogan and Matt Petersen, President of Global Green USA. Executives from Rentech, Audi, Bosch and Argonne National Laboratory will discuss the latest advances that have made clean diesel vehicles feasible options for a sustainable future, and the role synthetic and bio-based diesel fuels will play in the marketplace.

“With many thousands of miles already behind the wheel of Audi’s outstanding A3 TDI over the past year, Green Car Journal editors are well acquainted with the model’s thriftiness and fun-to-drive nature,” said Ron Cogan, Editor and Publisher of the Green Car Journal and Editor of GreenCar.com. “Running on a 100% low carbon fuel will make this 1,000 mile journey all the more satisfying,” Mr. Cogan said.

About Rentech, Inc.

Rentech, Inc. (www.rentechinc.com), incorporated in 1981, provides clean energy solutions. The Company’s Rentech-SilvaGas biomass gasification process can convert multiple biomass feedstocks into synthesis gas (syngas) for production of renewable fuels and power. Combining the gasification process with Rentech’s unique application of syngas conditioning and clean-up technology and the patented Rentech Process based on Fischer-Tropsch chemistry, Rentech offers an integrated solution for production of synthetic fuels from biomass. The Rentech Process can also convert syngas from fossil resources into ultra-clean synthetic jet and diesel fuels, specialty waxes and chemicals. Final product upgrading and acid gas removal technologies are provided under an alliance with UOP, a Honeywell company. Rentech develops projects and licenses these technologies for application in synthetic fuels and power facilities worldwide. Rentech Energy Midwest Corporation, the Company’s wholly-owned subsidiary, manufactures and sells nitrogen fertilizer products including ammonia, urea ammonia nitrate, urea granule, and urea solution in the corn-belt region of the central United States. Rentech has been recognized by Biofuels Digest as one of the “50 Hottest Companies in Bio-energy” and has been named as one of the “Biofuels Digest Companies of the Year” for its recent innovations and achievements, particularly in aviation biofuels.

About the Green Car of the Year Tour^™

The Green Car of the Year Tour^™ is sponsored by Robert Bosch LLC, which manufactures the common rail piezo injectors, fuel pump, and sophisticated electronic engine controls that help clean diesel vehicles achieve their high fuel economy, low emissions, and 50-state emissions certification.

Safe Harbor Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 about matters such as the Company’s development of a proposed synthetic fuels facility in Rialto, California, the emissions profile of the renewable power and fuels to be produced at the facility and the characteristics of the renewable fuels to be produced. These statements are based on management’s current expectations and actual results may differ materially as a result of various risks and uncertainties. \Other factors that could cause actual results to differ from those reflected in the forward-looking statements are set forth in the Company’s prior press releases and periodic public filings with the Securities and Exchange Commission, which are available via Rentech’s web site at www.rentechinc.com. The forward-looking statements in this press release are made as of the date of this press release and Rentech does not undertake to revise or update these forward-looking statements, except to the extent that it is required to do so under applicable law.

Iteris (ITI) Collaborates with Qualcomm to Deliver Enhanced Safety Data

SANTA ANA, Calif.–(BUSINESS WIRE)– Iteris, Inc. (NYSE Amex: ITI), a leader in the traffic management market that focuses on the application and development of advanced technologies, today announced an agreement with Qualcomm Incorporated, a leading provider of integrated wireless systems and services to transportation and logistics companies, to deliver safety data to trucking fleets. The data will be captured by Iteris’ Lane Departure Warning systems and Meritor WABCO’s SmartTrac and OnGuard active safety systems via Qualcomm’s Mobile Computing Platform 100 and 200 Series.

The solution by Iteris, Meritor WABCO, and Qualcomm provides a single point of access to synchronize and review driver performance data on braking events, stability control events, following distances, and lane-departure warnings for individual drivers as well as the entire fleet. It uses information transmitted from the vehicle by the fleet’s mobile computing platform to provide fleet operators with comprehensive fleet-wide safety summaries, and the ability to drill down to detailed information on individual drivers and events. The solution enhances Qualcomm’s Analytics Manager service, which takes data from numerous sources and converts it into actionable information by leveraging easy-to-use visual tools such as dashboards, graphs, and tables. The result is a holistic view into a fleet’s operational and safety performance, and the ability to make timelier and more informed business decisions.

With this solution, fleet managers at transportation and logistics companies using Qualcomm’s onboard fleet management technology can more easily identify risky driving behavior and provide drivers with the training that the fleet managers deem appropriate to reinforce safe driving practices.

“Iteris is delighted to collaborate with Qualcomm, a leader in mobile information systems and services for commercial vehicles,” said Mr. Abbas Mohaddes, president and chief executive officer of Iteris. “This agreement enables Iteris and Meritor WABCO to integrate best-in-class driver performance and safety data for fleets with Qualcomm’s industry leading Mobile Computing Platform Series.”

“Iteris’ SafetyDirect is an ideal complement to Qualcomm’s extensive suite of safety services,” stated Norm Ellis, vice president of sales, services, and marketing of Qualcomm Enterprise Services. “Iteris and Meritor WABCO possess unique, high value truck safety data, which can help further enhance the comprehensive safety profile for Qualcomm’s fleet customers.”

About Iteris, Inc.

Iteris, Inc. is a leader in the traffic management market focused on the development and application of advanced technologies that reduce traffic congestion, minimize the environmental impact of traffic congestion, and improve the safety of surface transportation systems infrastructure. Combining outdoor image processing, traffic engineering, and information technology, Iteris offers a broad range of Intelligent Transportation Systems and driver safety solutions to customers worldwide. Iteris is headquartered in Santa Ana, California, with offices throughout North America and in Europe and Asia. Investors are encouraged to contact us at 888-329-4483, or at www.iteris.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “can,” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the performance, acceptance uses and expected benefits of our technology including SafetyDirect, our market opportunities both domestically and abroad and our strategies and future prospects. These statements are subject to change and we undertake no obligation to revise or update publicly any forward-looking statements for any reason. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Important factors that may cause such a difference include, but are not limited to the market acceptance of our technologies and of the products that incorporate our technologies; commercial vehicle and automotive production schedules and agendas; the timing and successful completion of customer qualification of our products and the risks of non-qualification; market acceptance of our lane departure warning and SafetyDirect systems and the vehicles that incorporate them; our ability to specify, develop, complete, introduce, market, and transition our products and technologies to volume production in a timely manner; the potential unforeseen impact of product offerings from competitors and other competitive pressures; and the general economic and political conditions and specific conditions in the markets we address, including the general economic slowdown and volatility in the automotive and commercial vehicle sector. Further information on Iteris, Inc., including additional risk factors that may affect our forward-looking statements, is contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).

Ym Biosciences (YM.TO) Appoints Dr. Nick Glover as Chief Executive Officer

MISSISSAUGA, ON, Oct. 14 /PRNewswire-FirstCall/ – YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced it has appointed Dr. Nick Glover as Chief Executive Officer of the Company to be effective at the Company’s Annual General Meeting on November 18, 2010. Dr. Glover will also be nominated as a Director of the Company at that time. Mr. David Allan, who has been Chairman of the Company since its founding in 1994 and CEO since 1998, will continue to serve as Chairman of YM’s Board of Directors.

“Given the rapid progress being made with our recently acquired CYT387 JAK inhibitor program, the ongoing advancement of nimotuzumab globally, and the compelling prospects for the vascular disrupting agent CYT997, this is the ideal time to strengthen our team with strong leadership to advance these programs energetically,” said David Allan, Chairman and CEO of YM BioSciences. “In addition to his professional and academic qualifications, Nick has served as COO and President for the last several months and has demonstrated to the Board that he is an exceptional candidate with the right experience and skills to lead YM. I look forward to working with Nick through this transition in my role as Chairman and will continue to support YM’s relationships with the investment community.”

“David is a pioneer in our industry, having built YM BioSciences since its inception into a strong and vibrant company with a portfolio of promising late-stage products supported by a healthy balance sheet,” said Dr. Nick Glover, President and COO of YM BioSciences. “David’s approach of focusing primarily on drug development and his strategies for reducing risk via a diversified portfolio model and licensing philosophy were uncommon at the time of the Company’s founding and have since been adopted by many companies. We are grateful for David’s vision and astute leadership and welcome the ongoing guidance he will provide.”

Dr. Glover joined YM in June 2010 and is currently serving as President and COO. He was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. In addition to his operational experience, Dr. Glover has a background in business development and prior to joining Viventia was an investment manager for a leading venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada.

Annual Meeting

YM BioSciences’ Annual Meeting of Shareholders will be held on November 18, 2010 at 4:00 p.m. ET at the offices of Ogilvy Renault, 200 Bay Street, Suite 3800, Toronto, Ontario. The management proxy circular documents and annual financial documents will be mailed to shareholders on October 15^th, 2010 and are available online at www.ymbiosciences.com, www.edgar.com and www.sedar.com.

About YM BioSciences

YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with a potential best-in-class side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM’s licensees. CYT997 is a uniquely orally-available agent with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM’s three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia (formerly Cytopia) which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Spartan (SPTN) Stores Declares Quarterly Dividend

Oct. 14, 2010 (Business Wire) — Spartan Stores, Inc., (Nasdaq:SPTN) today announced that its Board of Directors declared a quarterly cash dividend of $0.05 per common share. The dividend is payable on December 15, 2010 to shareholders of record as of the close of business on December 1, 2010. As of September 30, 2010, there were approximately 22,625,197 common shares outstanding.

About Spartan Stores

Grand Rapids, Michigan-based Spartan Stores, Inc., (Nasdaq:SPTN) is the nation’s eleventh largest grocery distributor with 1.4 million square feet of warehouse, distribution, and office space located in Grand Rapids, Michigan. The Company distributes more than 40,000 corporate and national brand products to approximately 370 independent grocery stores in Michigan, Indiana and Ohio. Spartan Stores also owns and operates 97 retail supermarkets in Michigan, including Family Fare Supermarkets, Glen’s Markets, D&W Fresh Markets, Felpausch Food Centers and VG’s Food and Pharmacy.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are subject to a number of factors that could cause actual results to differ materially. The Company’s adoption of a dividend policy does not commit the board of directors to declare future dividends. Each future dividend will be considered and declared by the board of directors in its discretion. The ability of the board of directors to continue to declare dividends will depend on a number of factors, including the Company’s future financial condition and profitability and compliance with the terms of its credit facilities.

Additional information about the factors that may adversely affect these forward-looking statements is contained in Spartan Stores’ reports and filings with the Securities and Exchange Commission. Other risk factors exist and new risk factors may emerge at any time. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as predictions of future results. Spartan Stores undertakes no obligation to update or revise any forward-looking statements to reflect developments or information obtained after the date of this press release.

Spartan Stores, Inc.

Investor Contact:

Dave Staples

Executive Vice President & CFO

(616) 878-8793

Media Contact:

Jeanne Norcross

Vice President Corporate Affairs

(616) 878-2830

DRC (DRCO) Awarded $80 Million in New Business Contracts in Q3 2010

ANDOVER, Mass., Oct. 14, 2010 (GLOBE NEWSWIRE) — Dynamics Research Corporation (Nasdaq:DRCO), a leading provider of innovative management consulting, engineering, and technology solutions to federal and state governments, today reported that it received during the quarter ended September 30, 2010 new business contract awards having an estimated total value of $80 million. For 2010, year-to-date new business contract awards now stand at $142 million. The Company also reported that its current backlog of bids for new business, which have been submitted and are awaiting award, currently totals approximately $343 million, more than double at the same time a year ago.

The contract and task order awards reflect a mix of new orders in DRC’s target growth markets – homeland security, health care, training/human capital, business transformation, information security, selected civilian agencies, and high-priority defense programs. Eighty-four percent of the third quarter wins were prime contract awards, reflecting the Company’s direct access to customers with a broad portfolio of government and agency wide contracts. The contract wins for the quarter include a 4 year $12.5 million award for enterprise architecture services with the Department of Homeland Security Office of the Chief Information Officer, which has been protested.

With a strong backlog of bids awaiting award the Company expects new business awards for the calendar year 2010 to be in the vicinity of the $162 million posted for 2009.

“DRC is experiencing strong demand for our mission-critical technology management services and solutions, validated by another record level of prime contract new business wins in the third quarter,” said Jim Regan, DRC’s chairman and chief executive officer. “We’re pleased to see strong growth in the areas we have targeted for business expansion such as military medical health, the Department of Homeland Security where we continue to win new information architecture and security work under the EAGLE contract, and the Air Force unmanned air vehicle program where we have won another key task order under the DoD Logistics Maintenance and Supply Support contract. Having several significant new business bids submitted and awaiting award, we are well positioned for additional project awards in the quarters to come.”

DRC has reported sixteen consecutive quarters of year-over-year earnings increases and plans to announce third quarter 2010 financial results after market close on October 27, 2010.

About Dynamics Research Corporation

Dynamics Research Corporation (DRC) provides measurable performance improvements for government customers through the delivery of innovative management consulting, engineering and technology solutions. DRC offers the capabilities of a large company and the responsiveness of a small company, backed by a history of excellence and customer satisfaction. Founded in 1955, DRC is a publicly held corporation (Nasdaq:DRCO) and maintains more than 25 offices nationwide with major offices in Andover, Massachusetts and the Washington, D.C. region. For more information please visit our website at www.drc.com.

Safe harbor statements under the Private Securities Litigation Reform Act of 1995: Some statements contained or implied in this news release, may be considered forward-looking statements, which by their nature are uncertain. Consequently, actual results could materially differ. For more detailed information concerning how risks and uncertainties could affect the company’s financial results, please refer to DRC’s most recent filings with the SEC. The company assumes no obligation to update any forward-looking information.

CONTACT:  Darrow Associates, Inc.
          Investors:
          Chris Witty
          646.438.9385
          cwitty@darrowir.com

          Sage Communications  (for DRC)
          Media:
          Matt Warnock
          703.207.0941
          mattw@aboutsage.com

Computer Dynamics of Japan Selects Dot Hill 3000 Series Storage and Virtualization Software Solutions

LONGMONT, Colo. — Dot Hill Systems Corp. (Nasdaq: HILL), a provider of world-class storage solutions and software for OEMs, open storage partners and system integrators, today announced that it has signed an OEM agreement with Computer Dynamics, a leading storage solution provider in Japan. Under the terms of the agreement, Computer Dynamics will sell solutions based on Dot Hill’s iSN® storage virtualization software and the company’s full line of 3000 Series storage arrays.

Headquartered in Tokyo, Japan, Computer Dynamics delivers innovative and cost-effective storage solutions including RAID arrays, switches and tape libraries. For more than 28 years, Computer Dynamics has been providing cutting-edge storage and storage networking products to many industry sectors in Japan, including education, government, broadcasting, manufacturing, finance, and oil & gas.

“Given the price/performance leadership of the 3000 Series and the company’s richly featured storage virtualization software, Dot Hill was the logical storage partner for Computer Dynamics,” said Hiro Sakamoto, president, Computer Dynamics. “Dot Hill allows us to deliver highly scalable, high performance SAN storage and a broad range of advanced management and virtualization features to our diverse customer base.”

“With more than two decades of storage expertise and an extensive footprint in the Japanese market, Computer Dynamics is well equipped to leverage Dot Hill innovation to address the storage challenges of its IT customers,” said Garrett Wein, vice president worldwide OEM sales, Dot Hill Systems. “Dot Hill storage virtualization allows Computer Dynamics to deliver unified storage management and disaster recovery solutions for mixed storage environments and provides cross-platform features regardless of storage vendor platform or vintage. With the ability to manage storage as a single pool through its virtualization and DR capabilities, Dot Hill iSN makes it easier for IT managers to standardize storage management and processes.”

Based on a powerful, flexible virtualization engine, Dot Hill iSN solutions offer a rich set of features such as thin provisioning, snapshots, replication, migration and storage tiering. Dot Hill iSN can provision both Fibre Channel, NAS and iSCSI protocols and present file and block services simultaneously while scaling up to 6 petabytes (6PB) of storage capacity. Dot Hill iSN software can be loaded onto standard x86 hardware servers and is readily integrated into existing environments and is highly configurable to meet OEMs’ diverse requirements, enabling partners to create and market their own unique branded solutions.

Dot Hill’s next-generation 3000 Series of RAID arrays offers support for 8Gb Fibre Channel storage area networks (SANs), 10Gb iSCSI SANs, and dual interface 8Gb Fibre Channel/1Gb iSCSI SANs, along with optional Dot Hill AssuredRemote™ data management software for remote replication, AssuredCopy™ volume copy technology which enables the creation of independent data volume copies for additional data protection, and Dot Hill’s AssuredSnap™ snapshot capability for improved data availability and business continuity.

Dot Hill 3000 Series storage arrays are easily customized by partners and customers to meet varying performance, capacity, and other specific business requirements. Dot Hill storage arrays are equipped with a number of energy-saving features including Dot Hill’s patented EcoStor™ “green” battery-free alternative for cache memory, drive spin-down and DC power options. Dot Hill storage solutions scale to support up to 144 SAS, near-line SAS, SSD and SATA disk drives, totaling up to 192 terabytes of capacity based on today’s 2 TB disk drive capacities, and feature a 2U 12 or 24-drive rack-mount footprint.

About Dot Hill

Offering enterprise-class security, availability and data protection, Dot Hill provides responsive and adaptive storage solutions to meet 24/7/365 business demands. With Dot Hill, businesses can proactively safeguard and manage business data, and leverage operational efficiencies to save time, effort and expense today, while meeting the evolving business needs of tomorrow strategically and cost effectively. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in China, Germany, India, Israel, Japan, Singapore, United Kingdom, and the United States.

For more information, visit us at www.dothill.com.

HILL-G

Certain statements contained in this press release regarding matters that are not historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the statements. Forward-looking statements include statements regarding: the size and timing of orders placed by Computer Dynamics; any improvement to Dot Hill’s financial results due to its relationship with Computer Dynamics; the size of the Japanese data storage market; and the benefits or performance of Dot Hill’s products (including iSN solutions and its 3000 series storage arrays) in any particular environment. The risks that contribute to the uncertain nature of the forward-looking statements include: that the relationship between Dot Hill and Computer Dynamics may terminate at any time and does not require minimum purchases; changing customer preferences in the open systems computing market; and unforeseen supply, technological, intellectual property or engineering issues. Plus, there are many other risks not listed here that may affect Dot Hill’s business, as well as the forward-looking statements contained herein. To learn about such risks and uncertainties, you should read the risk factors set forth in the company’s public filings with the SEC, including the Forms 8-K, 10-K and 10-Q most recently filed by Dot Hill. All forward-looking statements contained in this press release speak only as of the date on which they were made.

Alanco/StarTrak (ALAN) Announces FY First Quarter Sales Up 25%

Oct. 14, 2010 (Business Wire) — Alanco Technologies, Inc. (NASDAQ: ALAN) today announced preliminary unaudited sales results for its fiscal first quarter ended September 30, 2010. StarTrak Systems, the Company’s sole operating subsidiary following the recent divestiture of underperforming assets, reported first quarter sales totaling approximately $3.7 million, a 25% increase compared to the prior year first quarter results. During the first quarter the Company reported adding a record 24 new accounts in diverse refrigerated transport market segments including: truckload, intermodal, food service, private fleet, life sciences and international refrigeration applications.

Tom Robinson, StarTrak Executive Vice President, commented, “The record number and diversity of our 24 first quarter account additions demonstrate the growing adoption of StarTrak’s information technology services throughout the refrigerated transport market. The first quarter’s sales were about 10-15% less than anticipated due to an industry-wide shortage of certain electronic components which delayed shipment of a portion of our hardware backlog to the second quarter. With our existing strong backlog, and assuming modest improvement in electronic component availability, we anticipate sales to increase approximately 30% for the fiscal second quarter.”

Alanco Technologies, Inc. provides wireless monitoring and asset management solutions through its StarTrak Systems subsidiary. StarTrak Systems is the dominant provider of tracking, monitoring and control services to the refrigerated or “Reefer” segment of the transportation marketplace, enabling customers to increase efficiency and reduce costs of the refrigerated supply chain. For more information, visit the Alanco website at www.alanco.com or StarTrak Systems at www.startrak.com.

EXCEPT FOR HISTORICAL INFORMATION, THE STATEMENTS CONTAINED IN THIS PRESS RELEASE ARE FORWARD-LOOKING STATEMENTS MADE PURSUANT TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. ALL SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO, AND ARE QUALIFIED BY, RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY THOSE STATEMENTS. THESE RISKS AND UNCERTAINTIES INCLUDE, BUT ARE NOT LIMITED TO, REDUCED DEMAND FOR INFORMATION TECHNOLOGY EQUIPMENT; COMPETITIVE PRICING AND DIFFICULTY MANAGING PRODUCT COSTS; DEVELOPMENT OF NEW TECHNOLOGIES THAT MAKE THE COMPANY’S PRODUCTS OBSOLETE; RAPID INDUSTRY CHANGES; FAILURE OF AN ACQUIRED BUSINESS TO FURTHER THE COMPANY’S STRATEGIES; THE ABILITY TO MAINTAIN SATISFACTORY RELATIONSHIPS WITH LENDERS AND REMAIN IN COMPLIANCE WITH FINANCIAL LOAN COVENANTS AND OTHER REQUIREMENTS UNDER CURRENT BANKING AGREEMENTS; AND THE ABILITY TO SECURE AND MAINTAIN KEY CONTRACTS AND RELATIONSHIPS.

Corporate Contact:

Alanco Technologies, Inc.

John Carlson, Exec VP & CFO

480-505-4869

or

Investor Relations Contact:

Institutional Marketing Services (IMS)

John Nesbett/Jennifer Belodeau

203-972-9200

Motricity (MOTR) Announces Its End-to-End, Mobile as a Service Offering

BELLEVUE, Wash., Oct. 12, 2010 (GLOBE NEWSWIRE) — Motricity (Nasdaq:MOTR), a leading provider of mobile Internet services announced its end-to-end Mobile as a Service offering, a comprehensive solution that combines the mCore Platform and solution suite, cloud-based infrastructure, managed and professional services into one integrated offering to empower every aspect of the operator’s mobile data services business. Through Motricity’s end-to-end Mobile as a Service offering, operators are able to fully capitalize on the unmatched opportunities available in rapidly growing, emerging markets where availability of a true mobile Internet experience is still in its early stages.

“In today’s competitive mobile marketplace, operators are increasingly reliant on mobile data experts, like Motricity, to remain at the forefront of innovation. This is especially true in emerging markets where they are faced with the dual challenge of limited resources, and exploding demand for mobile data services,” said Ryan Wuerch founder and chief executive officer of Motricity. “Motricity’s end-to-end solution enables these operators to quickly and cost-effectively deliver a branded mobile experience that increases user adoption and allows them to attract and retain their highest value customers.”

Motricity’s Mobile as a Service offering includes the following four key components:

• mCore Product Suite – Motricity’s mCore Product Suite is designed as an integrated set of products that work together to offer open access to the Internet through a highly-personalized and mobile-optimized experience. mCore integrates the best of the Web, offering commerce, social networking, information, entertainment, and Web discovery. mCore also provides powerful communications and advertising functionality. These capabilities, coupled with mCore’s deep user insight and recommendation engine, allow the operator to offer a compelling, user-centric experience, providing relevant information, communications, marketing and services to each subscriber, in real time.
• Cloud-Based Infrastructure – Motricity delivers its end-to-end Mobile as a Service offering through the cloud. Cloud computing provides a more flexible and cost-effective model for mobile data services, one that allows mobile data services teams to operate much more efficiently and respond faster to consumer demands. This operator grade infrastructure includes SLA backed hosting facilities and geo-redundant data centers located across the globe and includes managed network operations, information security management, application services, data management and application hosting. This approach enables rapid development and implementation cycles for new offerings and global leverage with regard to investment, innovation and best practices.
• Professional Services – Motricity’s Professional Services provide expert project management, encompassing everything required to implement the operator’s mobile data experience. By providing customization, design, implementation, integration and roll-out of the mCore Platform and solution suite into the operator’s network, Motricity is able to deploy the largest and most complex mobile data environments across multiple operators and geographies with an operator-grade level of quality and reliability.
• Managed Services – Motricity’s Managed Services deliver all the support an operator needs to effectively optimize and run their overall mobile data experience. Ranging across application, infrastructure and business management on an ongoing basis, these services include everything from application monitoring and content merchandising, to program management and marketing support. Motricity manages the operator’s mobile data services infrastructure on behalf of its customers providing a comprehensive end-to-end solution.

This unified offering sets Motricity apart in the competitive mobile data services industry. Companies worldwide depend on Motricity’s products, services and expertise to reinforce their brand, drive revenue and ensure secure and effective delivery of their mobile content. Motricity will continue to focus on integrating and delivering innovative technology through this comprehensive offering of rich mobile applications, robust hosting and infrastructure services and expertise in professional and managed services.

“Our end-to-end Mobile as a Service offering allows Motricity to attract and retain a global portfolio of operator customers and expand upon these relationships as they experience our product’s measurable results,” said Wuerch. “Motricity sits at the center of the mobile ecosystem and will continue to deliver on its vision of empowering your mobile experience.”

About Motricity

Motricity (Nasdaq:MOTR) is a leading mobile data solutions provider exclusively focused on the rapidly growing mobile Internet market. It serves some of the world’s largest mobile operators, simplifying the mobile Internet and creating a personalized mobile experience for subscribers. Motricity helps companies leverage the power of mobility to make direct, personalized connections with their customers. For more information, visit www.motricity.com or follow the company on Twitter @motricity.

The Motricity, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7813

Local.com (LOCM) Reports Preliminary Third Quarter 2010 Financial Results

IRVINE, Calif.–(BUSINESS WIRE)– Local.com Corporation (NASDAQ:LOCM – News), a leading local search site and network, today announced that based on unaudited preliminary results for the three months ended Sept. 30, 2010, the company expects revenue to be between $22.5 million and $22.7 million.

The company also said it expects record Adjusted Net Income to be between $4.7 million and $5.0 million or $0.27 to $0.29 per diluted share, which is higher than its previous guidance and primarily due to the higher margins achieved from sales of newly launched products utilizing the recently acquired OCTANE360 platform.

The company has received significant interest in its new product portfolio from existing and potential partners. Since these products have a limited record in the marketplace, the company cautions that there may not be similar transactions in future periods; and even if there are, those transactions may not have similar financial characteristics.

In accordance with normal procedures, these unaudited preliminary revenue and earnings results are subject to further review and completion by the company and its auditors.

“We believe our third quarter sales of OCTANE360-based products represent early validation of this acquisition. Integration of the OCTANE360 product suite into our sales and business development channels is ahead of schedule, and we continue to orient the company towards the sale of these higher volume, higher value ad products for our small business customers,” said Local.com chief executive officer, Heath Clarke. “Revenue came in slightly lower than expected due to lower traffic, almost entirely offset by increased monetization over the second quarter.”

Key Third Quarter Operating Highlights:

• Traffic – In Q3 2010, Owned & Operated (O&O) traffic was 50 million monthly unique visitors (MUVs), up 15 percent from the year ago period.
• Organic Traffic – O&O organic traffic was 5 million MUVs, flat from the year ago period. Organic traffic is defined as all non-SEM sourced traffic on O&O websites.
• Monetization of Traffic – Revenue per thousand visitors was $266 for the quarter, down 1 percent from the year ago period.
• Network Sites – The company ended Q3, 2010 with over 1,000 Network sites, and over 82,000 local domains under management.
• Small Business Subscribers – The company ended Q3 2010 with over 60,000 small business subscribers.

The preliminary third quarter 2010 financial results are being disclosed because Adjusted Net Income is expected to be significantly higher than previously announced guidance. The company does not intend to release preliminary financial results in future periods unless such results differ materially from prior guidance.

The regularly scheduled conference call to discuss the company’s third quarter 2010 financial results will be announced at a later date.

Adjusted Net Income is defined as net income excluding: provision for income taxes; interest and other income (expense), net; depreciation; amortization; stock-based compensation charges; gain or loss on warrant revaluation and non-recurring items.

An explanation of the company’s use of non-GAAP financial measures, including the limitations of such measures relative to GAAP measures is included below, along with a table that reconciles expected net income to expected Adjusted Net Income for the company’s third quarter 2010 financial results.

For more information on the company please visit: http://corporate.local.com.

About Local.com^®

Local.com Corporation (NASDAQ:LOCM – News) owns and operates a leading local search site and network in the United States. The company uses patented and proprietary technologies to provide over 20 million consumers each month with relevant search results for local businesses, products and services on Local.com and over 1,000 partner sites. Local.com owns or manages over 100,000 geo-category domain sites, and tens of thousands of small business customers use Local.com products and services to reach consumers using a variety of subscription, performance and display advertising and website products. To advertise, or for more information visit: www.local.com.

Forward Looking Statements

All statements other than statements of historical fact included in this document regarding our anticipated financial position, business strategy and plans and objectives of our management for future operations, are forward-looking statements. When used in this report, words such as ‘anticipate,’ ‘believe,’ ‘estimate,’ ‘plans,’ ‘expect,’ ‘intend,’ ‘projects,’ ‘feel’ and similar expressions and phrases, as they relate to Local.com or our management, identify forward-looking statements. Any forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to our management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, our ability to monetize the Local.com domain, our ability to incorporate our local-search technologies, our ability to market the Local.com domain as a destination for consumers seeking local-search results, our ability to grow our business by enhancing our local-search services, including through businesses we acquire, the possibility that the information and estimates used to predict anticipated revenues and expenses associated with the businesses we acquire are not accurate, difficulties executing integration strategies or achieving planned synergies, the possibility that integration costs and go-forward costs associated with the businesses we acquire will be higher than anticipated, our ability to increase the number of businesses that purchase our subscription advertising and other business products, our ability to expand our advertiser and distribution networks, our ability to integrate and effectively utilize our acquisitions’ technologies, our ability to develop our products and sales, marketing, finance and administrative functions and successfully integrate our expanded infrastructure, as well as our dependence on major advertisers, competitive factors and pricing pressures, changes in legal and regulatory requirements, and general economic conditions. Any forward-looking statements reflect our current views with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this paragraph. Unless otherwise stated, all site traffic and usage statistics are from third-party service providers engaged by the company.

Our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K, and other Securities and Exchange Commission filings discuss the foregoing risks as well as other important risk factors that could contribute to such differences or otherwise affect our business, results of operations and financial condition. The forward-looking statements in this release speak only as of the date they are made. We undertake no obligation to revise or update publicly any forward-looking statement for any reason.

Non-GAAP Financial Measures

This press release includes the non-GAAP financial measure of “Adjusted Net Income” which we define as net income excluding: provision for income taxes; interest and other income (expense), net; depreciation; amortization; stock based compensation charges; gain or loss on warrant revaluation; and non-recurring items. Adjusted Net Income, as defined above, is not a measurement under GAAP. Adjusted Net Income is reconciled to net income which we believe is the most comparable GAAP measure. A reconciliation of net income to Adjusted Net Income is set forth at the end of this press release.

Management believes that Adjusted Net Income provides useful information to investors about the company’s performance because it eliminates the effects of period-to-period changes in income from interest on the company’s cash and marketable securities, expense from the company’s financing transactions and the costs associated with income tax expense, capital investments, stock-based compensation expense, warrant revaluation charges and non-recurring items which are not directly attributable to the underlying performance of the company’s business operations. Management uses Adjusted Net Income in evaluating the overall performance of the company’s business operations.

A limitation of non-GAAP Adjusted Net Income is that it excludes items that often have a material effect on the company’s net income and earnings per common share calculated in accordance with GAAP. Therefore, management compensates for this limitation by using Adjusted Net Income in conjunction with net income and net income per share measures. The company believes that Adjusted Net Income provides investors with an additional tool for evaluating the company’s core performance, which management uses in its own evaluation of overall performance, and as a base-line for assessing the future earnings potential of the company. While the GAAP results are more complete, the company prefers to allow investors to have this supplemental metric since, with reconciliation to GAAP; it may provide greater insight into the company’s financial results. The non-GAAP measures should be viewed as a supplement to, and not as a substitute for, or superior to, GAAP net income or earnings per share.

SIGA Technologies (SIGA) Selected for the Procurement of Smallpox Antiviral Drug for the Strategic National Stockpile

NEW YORK, Oct. 13, 2010 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the U.S. Department of Health and Human Services (HHS) has announced HHS’s intention to make an award to SIGA of a contract to deliver 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to SIGA’s status with the Small Business Administration. The award relates to a Request for Proposal issued by HHS’s Biomedical Advanced Research and Development Authority (RFP-BARDA-09-35). The base contract, if finalized, is expected to generate revenues of approximately $500 million, and the entire contract, if all options are exercised, is expected to generate revenues of approximately $2.8 billion.

The Small Business Administration issues noted above derive from HHS notification to SIGA that Chimerix, Inc. (Chimerix) has filed a small business size protest against SIGA after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. HHS designated the proposed contract as a small business set-aside at the time of the original solicitation in March 2009. SIGA intends to respond promptly to the Small Business Administration concerning Chimerix’s protest.

Dr. Eric A. Rose, SIGA’s Chairman and Chief Executive Officer, stated, “We are very proud that HHS has selected our groundbreaking drug, ST-246^®, for this important acquisition and believe that SIGA appropriately qualified as a small business concern for this procurement.”

Details of HHS’s March 11, 2009 request for proposal and subsequent amendments can be found on the Federal Business Opportunities website at www.fbo.gov/index?s=opportunity&mode=form&id=61e7acbe316f2c52bfe0cc8c4b4852fd&tab=core&_cview=1. SIGA expects the proposed contract to be executed following resolution of the Chimerix protest; however, there can be no assurance concerning the outcome of the small business size protest.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA’s web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding SIGA’s ability to offer its products for sale to the U.S. government and statements regarding execution of the contract described above or the timing or outcome of the pending protest. Statements other than statements of historical fact are forward-looking statements, and may be identified by, among other things, forward-looking language such as the words or phrases “expect,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “project,” “scheduled to,” “seek,” “should,” “would,” “will be,” “will continue,” “will likely result,” “targeted,” or the negative of those terms, or other similar words and phrases or by discussions of intentions or plans. Forward-looking statements are based on management’s estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection for its products, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that BARDA may not complete the procurement set forth in its solicitation for the acquisition of smallpox antiviral for the strategic national stockpile, or may complete it on different terms, (ix) the risk that the pending protest or another future protest may cause a contract award to us through the RFP process to be delayed or overturned, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts, and (xi) the effect of federal, state, and foreign regulation on SIGA’s businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC’s Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

Cheviot Financial Corp. (CHEV) to Acquire First Franklin Corporation (FFHS)

CINCINNATI — Cheviot Financial Corp. (Nasdaq: CHEV), the parent company of Cheviot Savings Bank, today announced that it has entered into an agreement to purchase First Franklin Corporation (Nasdaq: FFHS), the Blue Ash-based parent company of The Franklin Savings and Loan Company.  Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, stockholders of First Franklin will be entitled to receive $14.50 in cash for each share they hold.

The deal will double Cheviot Savings Bank’s branch network and increase its asset size by approximately $250 million to over $600 million.

“The purchase of First Franklin allows us to expand our footprint while transforming our company into the largest publicly-held community bank in Hamilton County,” said Thomas J. Linneman, President and CEO of Cheviot Financial and Cheviot Savings Bank.  “In completing this acquisition, we reached agreement with another historic Cincinnati financial institution, both of which have focused on providing personal, quality customer service.  We believe the transaction will be accretive to Cheviot Financial’s earnings per share and, following completion of the acquisition, the bank will have capital of over two times the minimum regulatory requirement.”

Jack Kuntz, First Franklin’s Chairman, President and CEO said, “With the dramatic changes occurring in the banking industry, we think this merger is an excellent result for our stockholders.  The purchase price of $14.50 per share provides a return to the First Franklin stockholders of 1.85 times the October 12, 2010 closing market price of $7.82 per share and 112% of the June 30, 2010 book value of $12.95 per share.  The First Franklin board followed a structured process with the guidance of an experienced investment banking firm to seek a qualified buyer able to deliver a solid return for our stockholders.  The combination of these two great Cincinnati financial institutions also provides increased opportunities for our customers and our employees.”

Following completion of the transaction, Cheviot Savings Bank will move up to 8th in deposit market share in Hamilton County and will rank 12th in deposit market share in the Cincinnati Metropolitan Statistical Area (MSA), based on the most recently available FDIC data.

The transaction is subject to certain conditions, including requisite regulatory approval and the approval of First Franklin’s stockholders, but is not subject to any financing contingency.  It is expected the merger will close during the first quarter of 2011.  Cheviot Financial is being advised on the transaction by RP Financial, LC. and Luse Gorman Pomerenk & Schick, P.C.  First Franklin is being advised on the transaction by ParaCap Group, a subsidiary of Paragon Capital Group, LLC, and by Vorys, Sater, Seymour and Pease LLP.

Once approved, Linneman added, “Cheviot Savings Bank is committed to bringing its best banking practices to new and current customers throughout Southwestern Ohio, Southeastern Indiana, and Northern Kentucky.”

Cautionary Notice Regarding Forward Looking Statements

Certain statements in this press release contain forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections of future company or industry performance based on management’s judgment, beliefs, current trends and market conditions. Actual outcomes and results may differ materially from what is expressed, forecasted or implied in any forward-looking statement. Forward-looking statements made by First Franklin or Cheviot Financial may be identified by the use of words such as “will,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “seeks,” “estimates,” and similar expressions. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this document. For example, (1) First Franklin may be unable to obtain stockholder approval required for the transaction; (2) regulatory approvals required for the transaction may not be obtained, or required regulatory approvals may delay the transaction or result in the imposition of conditions that could have a material adverse effect on First Franklin or Cheviot Financial or cause the parties to abandon the transaction; (3) conditions to the closing of the transaction may not be satisfied; (4) the business of First Franklin or Cheviot Financial may suffer as a result of uncertainty surrounding the transaction; and (5) First Franklin or Cheviot Financial may be adversely affected by other economic, business, and/or competitive factors.  First Franklin and Cheviot Financial undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.  Readers are cautioned not to place undue reliance on these forward-looking statements.

Additional Information and Where to Find It

In connection with the proposed transaction, a proxy statement of First Franklin and other materials will be filed with the Securities Exchange Commission (“SEC”).  INVESTORS ARE URGED TO READ THE PROXY STATEMENT AND THESE OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT FIRST FRANKLIN CORPORATION AND THE PROPOSED TRANSACTION.  Investors will be able to obtain free copies of the proxy statement (when available) as well as other filed documents containing information about First Franklin on the SEC’s website at http://www.sec.gov.  Free copies of First Franklin’s SEC filings are also available from First Franklin Corporation, 4750 Ashwood Drive, Cincinnati, Ohio 45241, Attention: Secretary.

Participants in the Solicitation

First Franklin and its executive officers, directors, other members of management, employees and Cheviot Financial may be deemed, under SEC rules, to be participants in the solicitation of proxies from First Franklin’s stockholders with respect to the proposed transaction. Information regarding First Franklin’s executive officers and directors is set forth in First Franklin’s definitive proxy statement for its 2010 annual meeting of stockholders, which was filed with the SEC on April 22, 2010. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed transaction.

RightNow (RNOW) Announces Preliminary Third Quarter 2010 Financial Results

Oct. 12, 2010 (Business Wire) — RightNow® Technologies (NASDAQ: RNOW), today announced unaudited preliminary financial information for the third quarter ended September 30, 2010. Based on preliminary information and subject to the quarterly accounting close and review procedures, the Company currently expects to report revenue of approximately $48 million, GAAP earnings per share of approximately $0.07, and non-GAAP earnings per share, which excludes stock-based compensation, of approximately $0.14 for the third quarter of 2010. These preliminary anticipated results exceed the Company’s previous guidance for the third quarter of revenue of approximately $45 million, GAAP earnings per share of approximately $0.05, and non-GAAP earnings per share of approximately $0.12 as provided on July 28, 2010.

“We had a great third quarter demonstrating our continued momentum in the market,” stated Greg Gianforte, CEO and founder. “As organizations focus more attention on customer experience across the web, contact center and social, we believe we are in a unique position to seamlessly serve their mission critical needs. We are looking forward to the kick-off of our annual customer summit in Colorado Springs tomorrow, where we bring together hundreds of our customers and partners to share ideas, promote the RightNow community and drive our vision of ridding the world of bad experiences.”

RightNow will be hosting a meeting with analysts at its annual user conference today at 8:30 a.m. MT (10:30 a.m. ET) during which the company will discuss these preliminary results and other related business matters. The analyst meeting and question and answer session will be webcast at http://investor.rightnow.com/index.cfm.

In addition, RightNow will release its final earnings results for the third quarter ended September 30, 2010 after the market close on Thursday, October 28, 2010. The company will host a conference call to discuss the results at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day. To access the call on October 28, 2010, please dial (877) 638-9569, or outside the U.S. (914) 495-8536, at least five minutes prior to the 2:30 p.m. MT start time. A live webcast of the call will also be available at http://investor.rightnow.com/index.cfm under the Investor Webcasts menu. An audio replay will be available between 5:30 p.m. MT October 28, 2010 and 9:59 p.m. MT November 11, 2010 by calling (800) 642-1687 or (706) 645-9291, with Conference ID 16293024. The replay will also be available on our website at http://investor.rightnow.com.

About RightNow Technologies

RightNow is helping rid the world of bad experiences one consumer interaction at a time, eight million times a day. RightNow CX, the customer experience suite, helps organizations deliver exceptional customer experiences across the web, social networks and contact centers, all delivered via the cloud. With more than eight billion customer interactions delivered, RightNow is the customer experience fabric for nearly 2,000 organizations around the globe. To learn more about RightNow, go to www.rightnow.com.

RightNow is a registered trademark of RightNow Technologies, Inc. NASDAQ is a registered trademark of The NASDAQ Stock Market LLC.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding projected results of operations and management’s future strategic plans. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement.

The risks and uncertainties referred to above include, but are not limited to, the risk that the preliminary financial information in this press release will differ from the completed third quarter final results; our success in transitioning to a new President and Chief Operating Officer; general economic conditions; fluctuations in foreign currency exchange; our business model; our ability to develop or acquire and gain market acceptance for new products and enhancements to existing products in a cost-effective and timely manner; fluctuations in our earnings as a result of potential changes to our valuation allowance(s) on our deferred tax assets; the success of our efforts to integrate HiveLive’s personnel and processes, following our acquisition of that entity; the risk of asset impairment associated with the acquisition of HiveLive; the gain or loss of key customers; competitive pressures and other similar factors such as the availability and pricing of competing products and technologies and the resulting effects on sales and pricing of our products; our ability to expand or contract operations, manage expenses and grow profitability; the rate at which our present and future customers adopt our existing and future products and services; fluctuations in our operating results including our revenue mix and our rate of growth; fluctuations in backlog; the risk that our investments in partner relationships and additional employees will not achieve expected results; interruptions or delays in our hosting operations; breaches of our security measures; our ability to protect our intellectual property from infringement, and to avoid infringing on the intellectual property rights of third parties; any unanticipated ambiguities in fair value accounting standards; the amount and timing of any stock repurchases under our stock repurchase program; fluctuations in our operating results from the impact of stock-based compensation expense; our ability to manage and expand our partner relationships; our ability to hire, retain and motivate our employees and manage our growth; the impact of potential future acquisitions, if any; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, quarterly reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. The forward-looking statements in this release speak only as of the date they are made. We undertake no obligation to revise or update publicly any forward-looking statement for any reason.

Reconciliation of Preliminary Non-GAAP Earnings Per Share

[a] Estimated stock-based compensation expense to be recorded for the periods indicated in accordance with FASB Accounting Standards Codification, Topic 718, Compensation-Stock Compensation, which is effective for periods beginning January 1, 2006.

About Non-GAAP Financial Measures

Non-GAAP net income and diluted net income per share are supplemental measures of our performance that are not required by, or presented in accordance with GAAP. These non-GAAP financial measures are not intended to be used in isolation and should not be considered a substitute for net income and net income per share or any other performance measure determined in accordance with GAAP. We present non-GAAP net income and net income per share because we consider each to be an important supplemental measure of our performance.

Management uses these non-GAAP financial measures to make operational decisions, evaluate the Company’s performance, prepare forecasts and determine compensation. Further, management believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company’s performance when planning, forecasting and analyzing future periods. Our stock-based compensation expenses are expected to vary depending on the number of new grants issued, changes in our stock price, stock market volatility, expected option lives and risk-free rates of return, all of which are difficult to estimate. In calculating non-GAAP net income and net income per share, management excludes stock-based compensation expenses to facilitate its review of the comparability of the Company’s operating performance on a period-to-period basis because such expenses are not, in management’s view, related to the Company’s ongoing operating performance. Management uses this view of its operating performance for purposes of comparison with its business plan and individual operating budgets and resource allocation.

Management further believes that these non-GAAP financial measures are useful to investors in providing greater transparency to the information used by management in its operational decision making. We believe that the use of non-GAAP net income and net income per share also facilitate a comparison of RightNow’s underlying operating performance with that of other companies in our industry, which use similar non-GAAP financial measures to supplement their GAAP results.

Calculating non-GAAP net income and net income per share have limitations as an analytical tool, and readers should not consider these measures in isolation or as substitutes for GAAP net income and GAAP net income per share. In the future, we expect to incur additional stock-based compensation expenses and the exclusion of these expenses in the presentation of our non-GAAP financial measures should not be construed as an inference that these costs are unusual, infrequent or non-recurring. Investors and potential investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool, which include:

• Other companies inside and outside of our industry may calculate non-GAAP net income and net income per share differently than we do, limiting their usefulness as a comparative tool; and
• The Company’s income tax expense or benefit will be ultimately based on its GAAP taxable income and actual tax rates in effect, which may differ significantly from the effective tax rate used in our non-GAAP financial measures.

In addition, the adjustments to our GAAP financial measures reflect the exclusion of stock-based compensation expenses that are recurring and will be reflected in the Company’s financial results for the foreseeable future. The Company compensates for these limitations by providing specific information regarding the GAAP amount excluded from the non-GAAP financial measures. The Company further compensates for the limitations of our use of non-GAAP financial measures by presenting comparable GAAP measures more prominently. The Company evaluates the non-GAAP financial measures together with the most directly comparable GAAP financial measures.

Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with our GAAP net income and net income per share. For more information, see the consolidated operating statements and reconciliation of non-GAAP measurements contained in this press release.

FRNOW

Investor Relations:

The Blueshirt Group

Todd Friedman or Stacie Bosinoff

415-217-7722

todd@blueshirtgroup.com

stacie@blueshirtgroup.com

or

Corporate Communications:

RightNow Technologies

Jaia Zimmerman

650-653-4441 (Office)

650-464-8462 (Cell)

jzimmerman@rightnow.com

Johns Manville to Install Ascent Solar (ASTI) CIGS Modules

Oct. 12, 2010 (Business Wire) — Ascent Solar Technologies, Inc. (NASDAQ:ASTI) and Johns Manville, a Berkshire Hathaway company (NYSE: BRK.A, BRK.B) (JM), announced today, after extensive internal product development and testing, thin-film copper indium gallium (di)selenide (CIGS) laminated modules from Ascent Solar are ready for beta test deployment at the JM Technical Center (JMTC) in Littleton, Colo. The Ascent Solar IEC 61646 (20 year life expectancy) certified and UL certification (safety test) pending modules will be compared side-by-side against existing thin-film modules currently installed at JMTC.

“This is an important step forward in our ongoing collaboration with Ascent Solar,” noted Dr. Tim Swales, Johns Manville vice president of Research and Development. “The installation at our test site will provide the performance data we need in order to demonstrate the readiness of Ascent’s emerging high-power lightweight CIGS modules in order to make it available to our customers. As valued partners, we look forward to further collaboration and assessment of their product and ensuring our customers are successful.”

The test installation is done to collect performance data, evaluate architecture aesthetics and showcase the potential of Ascent Solar’s CIGS high-power modules against the current thin-film technology. For the pilot, installation modules have been applied to the top surface of the roofing membrane. The long-term objective is to integrate the modules into the roofing material itself as a factory-applied solution that JM markets under the Power Blanket brand. This external deployment will help set a standard for the integration and installation of lightweight flexible CIGS modules going forward as this will be the first time a CIGS monolithically integrated module manufactured using a plastic substrate has been integrated onto an existing commercial roofing installation for competitive commercial evaluation.

Ascent Solar President and CEO Farhad Moghadam added: “We are pleased that our product development with Johns Manville has progressed to this stage. Our lightweight, durable and high-power CIGS modules are an ideal match for true integration into the Johns Manville commercial roofing material product line. Installation onto the test site is a real indication that our product development is progressing and is crucial to our viability for larger system installations down the road.”

“Now that we have established IEC 61646 certification and have UL certification pending, we are pleased to launch pilot project installations with an industry leader like JM. Ascent Solar’s entry to the BAPV market with the highest power density flexible solutions and highest power modules will enable a new level of power production for flexible commercial applications,” stated Rafael Gutierrez, senior vice president of Sales and Marketing for Ascent Solar.

About Johns Manville

Johns Manville, a Berkshire Hathaway company (NYSE: BRK.A, BRK.B), is a leading manufacturer and marketer of premium-quality products for building insulation, mechanical insulation, commercial roofing, and roof insulation, as well as fibers and nonwovens for commercial, industrial, and residential applications. JM serves markets that include aerospace, automotive and transportation, air handling, appliance, HVAC, pipe and equipment, filtration, waterproofing, building, flooring, interiors, and wind energy. In business since 1858, the Denver-based company holds leadership positions in all of the key markets that it serves. JM employs approximately 6,500 people and operates 41 manufacturing facilities in North America, Europe and China. Additional information can be found at www.jm.com.

About Ascent Solar Technologies

Ascent Solar Technologies, Inc. is a developer of thin-film photovoltaic modules with substrate materials that can be more flexible and affordable than most traditional solar panels. Ascent Solar modules can be directly integrated into standard building materials, space applications, consumer electronics for portable power or configured as stand-alone modules for large scale terrestrial deployment. Ascent Solar is headquartered in Thornton, Colorado. For more information, go to www.AscentSolar.com.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission.

Interactive Intelligence (ININ) Announces Preliminary 2010 Third-Quarter Results

Oct. 12, 2010 (Business Wire) — Interactive Intelligence (Nasdaq: ININ), a global provider of unified IP business communications solutions, has announced preliminary results for its third quarter ended Sept. 30, 2010.

The company expects to report total revenues of between $41.0 million and $42.0 million, with net income on a GAAP basis of between $3.3 million and $3.8 million, and diluted earnings per share (EPS) on a GAAP basis of $0.18 to $0.20. Net income on a non-GAAP* basis is expected to be between $6.5 million and $7.3 million, with EPS of $0.35 to $0.39. Non-GAAP net income and EPS exclude stock-based compensation expense of approximately $1.0 million, or EPS of $0.06, and non-cash income tax expense of approximately $2.1 million to $2.4 million, or EPS of $0.11 to $0.13.

In the third quarter of 2009, the company reported revenues of $33.2 million, with GAAP net income and EPS of $2.8 million and $0.15, respectively, and non-GAAP net income and EPS of $5.7 million and $0.31, respectively. The 2009 third-quarter non-GAAP net income and EPS excluded stock-based compensation expense of $975,000, or EPS of $0.05, and non-cash income tax expense of $1.9 million, or EPS of $0.11.

Cash and investment balances as of Sept. 30, 2010 are expected to be about $85.5 million.

“We’re achieving better operating leverage from revenue growth driven by an increasing number of large transactions,” said Interactive Intelligence founder and CEO, Dr. Donald E. Brown. “We continue to execute on our strategy of moving up market, with nine orders over $1 million, including two of about $2 million each, and an additional 16 orders greater than $250,000 in the quarter. This growth is coming from both new and current premise-based customers, and from continued strong demand for our cloud-based communications offering. We currently anticipate annual revenue growth for 2010 of approximately 20 percent.”

The company has not completed preparation of its financial statements for the quarter ended Sept. 30, 2010. These preliminary results may be subject to adjustments and could change materially.

Interactive Intelligence plans to issue a press release announcing its final 2010 third-quarter results Nov. 1 at 4 p.m. Eastern daylight time. It will host a conference call Nov. 1 at 4:30 p.m. EDT, featuring Dr. Brown and the company’s CFO, Stephen R. Head. A live Q&A session will follow opening remarks.

To access the teleconference, please dial 1.877.324.1969 at least five minutes prior to the start of the call. Ask for the teleconference by the following name: “Interactive Intelligence third-quarter earnings call.”

The teleconference will also be broadcast live on the company’s investor relations’ page at http://investors.inin.com. An archive of the teleconference will be posted following the call.

About Interactive Intelligence

Interactive Intelligence Inc. (Nasdaq: ININ) is a global provider of unified business communications solutions for contact center automation, enterprise IP telephony, and business process automation. The company was founded in 1994 and has more than 3,500 customers worldwide. Interactive Intelligence is among Software Magazine’s top 500 global software and services suppliers, is a BusinessWeek “hot growth 50” company, and is among Fortune Small Business magazine’s top 100 fastest growing companies. The company is also positioned in the leaders’ quadrant of the Gartner Magic Quadrant for Contact Center Infrastructure, Worldwide report (Feb. 22, 2010). Interactive Intelligence employs approximately 800 people and is headquartered in Indianapolis, Indiana. It has 16 offices throughout North America, Latin America, Europe, Middle East, Africa and Asia Pacific. Interactive Intelligence can be reached at +1 317.872.3000 or info@inin.com; on the Net: www.inin.com.

* Non-GAAP Measures

The non-GAAP measures shown in this release exclude non-cash stock-based compensation expense for stock options and non-cash income tax expense. These measures are not in accordance with, or an alternative for, GAAP and may be different from non-GAAP measures used by other companies. Stock-based compensation expense is non-cash and income tax expense is primarily non-cash. Management believes that the presentation of non-GAAP results, when shown in conjunction with corresponding GAAP measures, provides useful information to management and investors regarding financial and business trends related to the company’s results of operations. Further, management believes that these non-GAAP measures improve management’s and investors’ ability to compare the company’s financial performance with other companies in the technology industry. Because stock-based compensation expense and non-cash income tax expense amounts can vary significantly between companies, it is useful to compare results excluding these amounts. Management also uses financial statements that exclude stock-based compensation expense related to stock options and non-cash income tax amounts for its internal budgets.

This release contains certain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially are the following: rapid technological changes in the industry; the company’s ability to maintain profitability; to manage successfully its growth; to manage successfully its increasingly complex third-party relationships resulting from the software and hardware components being licensed or sold with its solutions; to maintain successful relationships with certain suppliers which may be impacted by the competition in the technology industry; to maintain successful relationships with its current and any new partners; to maintain and improve its current products; to develop new products; to protect its proprietary rights adequately; to successfully integrate acquired businesses; and other factors described in the company’s SEC filings, including the company’s latest annual report on Form 10-K.

Interactive Intelligence Inc. is the owner of the marks INTERACTIVE INTELLIGENCE, its associated LOGO and numerous other marks. All other trademarks mentioned in this document are the property of their respective owners.